FINAL PROGRAM

SAN DIEGO, California
Hilton Bayfront San Diego
December 4-7, 2019

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14
Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18

www.ctad-alzheimer.com
Email: ctad@ant-congres.com
Organizing & Scientific Committees

Final program

Life Achievement Award

Program at a glance

Wednesday, December 4

Thursday, December 5

Friday, December 6

Saturday, December 7

Posters presentation

Theme 1: Clinical trials: Methodology

Theme 2: Clinical trials: Results

Theme 3: Clinical trials: Imaging

Theme 4: Clinical trials: Biomarkers including plasma

Theme 5: Clinical trials: Cognitive and functional endpoints

Theme 6: Cognitive assessment and clinical trials

Theme 7: Behavioral disorders and clinical trials

Theme 8: Health economics and clinical trials

Theme 9: Epidemiology and clinical trials

Theme 10: Clinical Trials: Animals Models

Theme 11: New therapies and clinical trials

Privileged partners

General information
CTAD Organizing Committee

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer’s
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco); Paul AISEN (San Diego); Kaj BLENNOW (Molndal); Merce BOADA (Barcelona); Maria CARRILLO (Chicago); Mony John DE LEON (New York); Steven DEKOSKY (Gainesville); Rachelle DOODY (Basel); Bruno DUBOIS (Paris); Howard FELDMAN (San Diego); Nick FOX (London); Giovanni B. FRISONI (Brescia, Geneva); Lutz FROELICH (Mannheim); Serge GAUTHIER (Montreal); Ezio GIACOBINI (Geneva); Michael GRUNDMANN (San Diego); Harald HAMPEL (Woodcliff Lake); Takeshi IWATSUBO (Tokyo); Ara KHACHATURIAN (Washington DC); Zaven KHACHATURIAN (Washington DC); Virginia LEE (Philadelphia); Constantine G. LYKETSOS (Baltimore); José Luis MOLINUEVO (Barcelona); Jean-Marc ORGOGOZO (Bordeaux); Ronald PETERSEN (Rochester); Craig W. RITCHIE (Edinburgh); Augustin RUIZ (Barcelona); Robert RISSMAN (San Diego); Marwan SABBAGH (Las Vegas); Stephen SALLOWAY (Providence); Rachel SCHINDLER (New York); Philip SCHELTENS (Amsterdam); Lon SCHNEIDER (Los Angeles); Eric SIEMERS (Philadelphia); Peter SNYDER (Rhode Island); Reisa SPEBLING (Boston); Yaakov STERN (New York); Jacques TOUCHON (Montpellier); John TROJANOWSKI (Philadelphia); Bruno VELLAS (Toulouse); Michael W. WEINER (San Francisco); Bengt WINBLAD (Stockholm)
Life Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Zaven Khachaturian, Ph.D., in recognition for his work on the foundations of AD clinical trials.


He is generally acknowledged as the ‘Founder - Chief Architect’ of the extramural research programs on Neurobiology of Aging and Alzheimer supported by the National Institution on Aging [NIA] / National Institutes of Health [NIH]. Formerly he served the dual role of Director, Office of Alzheimer's Disease, responsible for coordinating all Alzheimer's disease related activities NIH-wide; as well as the Associate Director for the Neuroscience and Neuropsychology of Aging Program (NNA) at the NIA/NIH. In these positions he was responsible for planning, developing and administering major national programs of research on Alzheimer's disease and brain aging e.g., Alzheimer's Centers, CERAD, ADCS, and other.

Outside government he has served as: Vice President of Research, University of Pittsburgh Medical Center [UPMC]; Professor, Health Services Research, Graduate School of Public Health, University of Pittsburgh; and Interim-Director for Pittsburgh Biotechnology Center, University of Pittsburgh; Founding Director, Ronald and Nancy Reagan Research Institute/Alzheimer's Association; President & CEO, Lou Ruvo Brain Institute [now the Cleveland Clinic Lou Ruvo Center for Brain Health].


His career spans several major positions requiring high level strategic decision making regarding public policies and program development. His research and scholarly interests include: neurobiology-neurophysiology of neuroplasticity-cognition / systems biology / calcium homeostasis – ‘Calcium Hypothesis’ / neurobiology of aging & dementia / public policy / politics of sciences / strategic planning & program development / research funding.
Program at a glance

Wednesday, DECEMBER 4

4.00 p.m  Opening Ceremony and CTAD Lifetime Achievement Award
4.30 p.m  KEYNOTE 1: How to interpret recent results in Alzheimer’s disease drug development?
5.00 p.m  SYMPOSIUM 1: New Results on the Relationship between Intensive Blood Pressure Control and Cognitive Function from SPRINT-MIND
5.45 p.m  LATE BREAKING ORAL COMMUNICATIONS
7.00 p.m  Welcome Networking Cocktail Reception and CTAD Band

Thursday, DECEMBER 5

8.00 a.m  TOPLINE RESULTS FROM PHASE 3 ADUCANUMAB STUDIES
9.00 a.m  ORAL COMMUNICATIONS SESSION
10.30 a.m  SYMPOSIUM 2: New Predictive Platforms for Advancing Drug Combination Approaches for Alzheimer Pathology
11.15 a.m  LATE BREAKING ORAL COMMUNICATION
11.30 a.m  ORAL COMMUNICATIONS SESSION
1.30 p.m  KEYNOTE 2: Overview of the NIA portfolio in AD clinical trials: Which new targets could be explored?
2.00 p.m  ROUNDTABLE: Pros and Cons of Weighted Composite Scores for Preclinical and Prodromal Alzheimer’s Disease
2.45 p.m  LATE BREAKING ORAL COMMUNICATIONS
4.00 p.m  SYMPOSIUM 3: Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies
4.45 p.m  ROUNDTABLE: BACE Inhibition: What do we know and what do we need to know?
5.45 p.m  LATE BREAKING ORAL COMMUNICATIONS

Friday, DECEMBER 6

8.00 a.m  LATE BREAKING ORAL COMMUNICATIONS
9.00 a.m  ORAL COMMUNICATIONS SESSION
10.30 a.m  KEYNOTE 3: And now what? Where are we headed in AD drug development?
11.00 a.m  SYMPOSIUM 4: AMBAR [Alzheimer’s Management By Albumin Replacement] Phase 2B/3 Trial: complete clinical, biomarker and neuroimaging results
1.00 p.m  ORAL COMMUNICATIONS SESSION
3.00 p.m  KEYNOTE 4: Next generation of multidomain lifestyle clinical trials: Design and implementation for proof of scientific concept and pragmatic sustainability
4.00 p.m  ORAL COMMUNICATIONS SESSION
5.00 p.m  LATE BREAKING ORAL COMMUNICATIONS

Saturday, DECEMBER 7

8.00 a.m  LATE BREAKING ORAL COMMUNICATIONS
8.30 a.m  ROUNDTABLE: Sex/gender consideration in clinical trials and potential improvements to clinical trial design
9.15 a.m  ORAL COMMUNICATIONS SESSION
10.45 a.m  SYMPOSIUM 5: Alzheimer’s Disease in Down Syndrome: New Insights and Opportunities
11.30 a.m  ORAL COMMUNICATIONS SESSION
2.30 p.m  End of conference
Wednesday, DECEMBER 4

4.00 p.m Opening Ceremony and CTAD Lifetime Achievement Award
Paul Aisen, Jacques Touchon, Bruno Vellas, Mike Weiner
This year the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research is awarded to Zaven Khachaturian, Ph.D., in recognition for his work on the foundations of AD clinical trials

4.30 p.m KEYNOTE 1
How to interpret recent results in Alzheimer’s disease drug development?
Introduction: Paul Aisen
Stephen Salloway, MD, MS - Chief of Neurology and Director of the Memory and Aging Program, Butler Hospital, Providence, RI, USA

5.00 p.m SYMPOSIUM 1
New Results on the Relationship between Intensive Blood Pressure Control and Cognitive Function from SPRINT-MIND
Chair: Kristine Yaffe, University of California at San Francisco (UCSF), San Francisco, CA, USA

PRESENTATION 1: Effect of intensive blood pressure control on subtypes of mild cognitive impairment
Sarah Gaussion, Wake Forest School of Medicine, Winston-Salem, NC, USA

PRESENTATION 2: Lessons Learned from Cognitive Outcomes in SPRINT: Neuropsychological Test Scores, Domain-Specific Cognitive Function, and Adjudicated Outcomes
Nicholas M. Pajewski, Wake Forest School of Medicine, Winston-Salem, NC, USA

PRESENTATION 3: Effect of intensive blood pressure control on brain MRI biomarkers
Ilya Nasrallah, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

5.45 p.m LATE BREAKING COMMUNICATIONS

5.45 p.m LB1 - HARMONY relapse-prevention study: pimavanserin significantly prolongs time to relapse of dementia-related psychosis
Erin FOFF (1), Jeffrey CUMMINGS (2), Maria SOTO-MARTIN (3), Bradley MCEVOY (1), Srdjan STANKOVIC (1)
(1) ACADIA Pharmaceuticals Inc., United States, (2) Cleveland Clinic Lou Ruvo Center for Brain Health, United States, (3) Gerontopole Alzheimer Clinical Research Center/University Hospital of Toulouse, France

6.00 p.m LB2 - Masupirdine (SUVN-502), a 5-HT6 receptor antagonist in combination with donepezil and memantine in moderate Alzheimer’s patients: Study outcomes from a phase-2 study
Jeffrey CUMMINGS (1,2), Alireza ATRI (3), Ramakrishna NIROGI (4), John IENI (4), Vinod GOYAL (4), Pradeep JAYARAJAN (4), Jyothsna RAVULA (4), Satish JETIA (4), Venkat JASTI (4)
(1) Department of Brain Health, School of Integrated Health Sciences, University of Nevada; Cleveland Clinic, Lou Ruvo Center for Brain Health, United States, (2) Cleveland Clinic Lou Ruvo Center for Brain Health, United States, (3) Banner Sun Health Research Institute, Banner Health, United States, (4) Suven Life Sciences, India

6.15 p.m LB3 - Results of the Reducing pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) Trial
Patrick G KEOHE (1), Nicholas TURNER (1), Elizabeth HOWDEN (1), Lina JARUTYTE (1), Shona CLEGG (2), Ian MALONE (2), Josephine BARNES (2), Carole SUDRE (3), Aileen WILSON (1), Jade THAI (1), Peter S BLAIR (1), Elizabeth COULTHARD (1), Athene LANE (1), Anthony P PASSMORE (4), Jodi TAYLOR (1), Henk-Jan MUTSAERTS (5), David LTHOMAS (2), Fox NICK (2), Ian WILKINSON (6), Yoav BEN-SHLOMO (1), Radar INVESTIGATORS (1)
(1) University of Bristol, United Kingdom, (2) University College London, United Kingdom, (3) Kings College, United Kingdom, (4) Queens University Belfast, United Kingdom, (5) Academic Medical Centre, United Kingdom, (6) Addenbrooke’s Hospital, United Kingdom
6.30 p.m  
**LB4** - A multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Safety and Efficacy of GV1001, a novel peptide mimicking human telomerase reverse transcriptase, for the Treatment of Moderate to Severe Alzheimer's Disease  
Seong-Ho KOH (1), Seong Hye CHOI (2), Jee Hyang JEONG (3), Chan Nyoung LEE (4), Young Soon YANG (5), Ae Young LEE (6), Jae-Hong LEE (7), Kyung Won PARK (8), Hyun Jeong HAN (9), Byeong Cha KIM (10), Jin Se PARK (11), Jee-Young LEE (12), Sangjae KIM (13)  
(1) Hanyang University Guri Hospital, Korea, Republic of, (2) Inha University Hospital, Korea, Republic of, (3) Ewha Womans University Mokdong Hospital, Korea, Republic of, (4) Korea University Anam Hospital, Korea, Republic of, (5) Veterans Health Service Medical Center, Korea, Republic of, (6) Chungnam National University Hospital, Korea, Republic of, (7) Asan Medical Center, Korea, Republic of, (8) Dong A University Hospital, Korea, Republic of, (9) Myongji Hospital, Korea, Republic of, (10) Chonnam National University Hospital, Korea, Republic of, (11) Inje University Haeundae Paik Hospital, Korea, Republic of, (12) Seoul National University Boramae Medical Center, Korea, Republic of, (13) Teloid Inc., United States

6.45 p.m  
**LB5** - Oral microbial dysbiosis and amyloid pathology in cognitively normal subjects  
Angela R. KAMER (1), Deepthi GULIVINDALA (1), Smruti PUSHLKAR (1), Qianhao LI (1), Lidia GLODZIK (2), Tracy BUTLER (2), Elizabeth PIRRAGLIA (1), Yi LI (2), Kumar ANNAM (1), Patricia CORBY (3), Henrik ZETTERBERG (4), Kaj BLENNOW (4), Deepak SAXENA (1), Mony J. DE LEON (2)  
(1) New York University, United States, (2) Cornell Medicine, United States, (3) UPENN, United States, (4) University of Gothenburg, Sweden

7.00 p.m  
**Welcome Networking Cocktail Reception and CTAD Band**  
*INDIGO Foyer and Terrace*
Thursday, DECEMBER 5

(late breaking communications LB6 to LB9 are on page 11)

8.00 a.m  TOPLINE RESULTS FROM PHASE 3 ADUCANUMAB STUDIES

9.00 a.m  ORAL COMMUNICATIONS SESSION
Chairs: Glenn Smith, Rema Raman

9.00 a.m  OC1 - Comparative Effectiveness of behavioral interventions in Mild Cognitive Impairment: 12-month outcomes of a Randomized Clinical Trial
Glenn Smith, University of Florida, Gainesville, FL, USA

9.15 a.m  OC2 - AADvac1 tau vaccine completing the phase 2 study: a paradigm shift for the AD treatment hypothesis
Matej Ondrus, Petr Novak, Zlka Norbert (1) AXON Neuroscience CRM Services SE, Slovakia

9.30 a.m  OC3 - Treatment with Donanemab, a ß-amyloid plaque-specific antibody, results in rapid and sustained reduction of amyloid measured by F-18 florbetapir imaging in Alzheimer’s disease
Stephen Lowe (1), Cynthia D. Evans (2), Sergey Schcherbinin (2), Yun-Jo Cheng (2), Arnaud Charil (2), Brian A. Willis (2), Gary Mo (2), Albert C. Lo (2), Adam S. Fleisher (3), Ann Hake (2), Masako Nakano (4), Jeffrey Dage (2), Michael Hodston (2), Paul Ardayfio (2), Guilherme Aguiar (5), Go Takaichi (4), Mark A. Mintun (2), Ronald B. Demattos (2), John R. Sims (2)
(1) Lilly Centre for Clinical Pharmacology, Singapore, (2) Eli Lilly and Company, United States, (3) Avid Pharmaceuticals, United States, (4) Eli Lilly Japan, K.K., Japan, (5) Eli Lilly and Company, United Kingdom

9.45 a.m  OC4 - Automatic speech recognition can deliver large-scale, remote assessments of cognition
Francesca Cormack PhD (1,2), Merina Su PhD (1), Jennifer H. Barnett PhD (1,2), Nick Taptiklis (1)

10.00 a.m Coffee Break and poster sessions / Posters P1 to P110 Themes 1,2,3,4 - INDIGO Foyer

10.30 a.m  SYMPOSIUM 2
New Predictive Platforms for Advancing Drug Combination Approaches for Alzheimer Pathology
Chairman: Lon Schneider, Keck School of Medicine of USC, Los Angeles, CA, USA

PRESENTATION 1: In Silico Screening of Medications for Slowing Alzheimer’s Disease Progression in a Clinical Trials Meta-database
Richard E. Kennedy, University of Alabama, Birmingham, AL, USA

PRESENTATION 2: Drug Combination Identification through Correlation between a Clinical Dataset and a Computational Model
Thomas J. Anastasio, University of Illinois at Urbana-Champaign, Urbana, IL, USA

PRESENTATION 3: Evaluating Pharmacodynamic Interactions in Drug Combinations Using Quantitative Systems Pharmacology Analysis of Clinical Trials
Hugo Geerts, In Silico Biosciences, Berwyn, PA, USA

11.15 a.m  LATE BREAKING ORAL COMMUNICATION
Chairs: Philip Scheltens, Alette Wessels

LB01 - Persistence Of BAN2401-Mediated Amyloid Reductions Post-Treatment: A Preliminary Comparison Of Amyloid Status Between The Core Phase Of BAN2401-6000-201 And Baseline Of The Open-Label Extension Phase In Subjects With Early Alzheimer’s Disease
Chad Swanson (1), Yong Zhang (1), Shobha Dhadda (1), Jinping Wang (1), June Kaplow (1), Heather Bradley (1), Martin Rabe (1), Keiichiro Totsuka (2), Robert Lair (3), Robert Gordon (3), Lynn Kramer (1)
(1) Eisai Inc., United States, (2) Eisai Co., Ltd., Japan, (3) Eisai Ltd., United Kingdom
Thursday, December 5

11:30 a.m

**ORAL COMMUNICATIONS SESSION**

**Chairs:** Philip Scheltens, Alette Wessels

**11:30 a.m**

**OC5 - Development of cognitive go/no-go decision-making criteria in early clinical development of agents to treat Alzheimer’s disease**

Alette Wessels, PhD (1), Chris J. Edgar PhD (2), Gregory Light, PhD (3), Pradeep Nathan, PhD (4), Eric Siemers, MD (5), Paul Maruff, PhD (6), John Harrison, PhD (7)

(1) Eli Lilly and Company, Indianapolis, IN, USA, (2) Cogstate Ltd, London, UK, (3) Department of Psychiatry, University of California, San Diego, USA, (4) SoseiHeptares, Cambridge, UK, (5) Department of Psychiatry, University of Cambridge UK, (6) School of Psychological Sciences, Monash University, Australia, (7) Cogstate Ltd, New Haven, CT, USA

**11:45 a.m**

**OC6 - Efficacy and safety results of REVERSE-SD, phase-2b clinical study of the selective p38α kinase inhibitor nelamipimod in early-stage Alzheimer’s disease (AD)**

Philip Scheltens (1), John Alam (2), John Harrison (1,3), Kelly Blackburn (2), Niels Prins (1,4)

(1) Department of Neurology and Alzheimer Center, Amsterdam UMC, Netherlands, (2) EIP Pharma, Inc, United States, (3) Metis Cognition Ltd, United Kingdom, (4) Brain Research Center, Netherlands

**12:00 p.m**

**OC7 - Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimer’s disease (CREAD/CREAD2): Biomarker results**

Tobias Bittner (1), Christina Rabe (2), David Clayton (2), Angelica Quartino (2), Sandra Sanabria Bohorquez (2), Nan Hu (2), Michael Rabbia (2), Harumi Shimizu (2), Udo Eichenlaub (3), Jillian Smith (4), Lee Honigberg (2), Dennis J. Selkoe (5), Susanne Ostrowitzki (2)

(1) F. Hoffmann-La Roche Ltd, Switzerland, (2) Genentech, Inc., United States, (3) Roche Diagnostics GmbH, Germany, (4) Roche Products Limited, United Kingdom, (5) Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, United States

**12:15 p.m**

**OC8 - DHA Brain Delivery Pilot Study: A randomized clinical trial**

Hussein Yassine (1), Isabella Cordova (1), Nicholas Choe (1), Xulei He (1), Brian Kavin (1), Naoko Kono (1), Giselle Kim (1), Alfred Fonteh (2), Howard Hodis (1), Lina D’orazio (1), Carol Mccleary (1), Helena Chui (1), Michael Harrington (2), Meredith Braskie (1), Wendy Mack (1), Lon Schneider (1)

(1) USC, United States, (2) HMRI, United States

**12:30 p.m**

Lunch (for pre-registered attendees) and Poster Sessions / Posters P1 to P110 Themes 1,2,3,4 - INDIGO Foyer

1:30 p.m

**KEYNOTE 2**

Overview of the NIA portfolio in AD clinical trials: Which new targets could be explored?

Introduction: Jacques Touchon

Eliezer Masliah, MD - Director of the Division of Neuroscience, National Institute on Aging (NIA), Bethesda, USA

2:00 p.m

**ROUNDTABLE**

Pros and Cons of Weighted Composite Scores for Preclinical and Prodromal Alzheimer’s Disease

Moderators: Sandrine Andrieu MD, PhD, Inserm, University of Toulouse, Toulouse, France, Pierre Tariot MD, Banner Alzheimer Insitute, Phoenix, AZ, USA

**PRESENTATION 1:** Important Considerations for Statistically Deriving Weighted Composite Scores for Alzheimer’s Disease

Suzanne Hendrix, Pentara Corp, Salt Lake City, UT, USA

**PRESENTATION 2:** The Weighting Game: What Impact Do Weights Have on Composite Scores - Are They Worth It?

Kun Jin, Statistical Team Leader, US Food and Drug Administrations, Washington, DC, USA
Thursday, DECEMBER 5

2.45 p.m  **LATE BREAKING ORAL COMMUNICATIONS**  
**Chairs: Bruno Vellas, Zahinoor Ismail**

2.45 p.m  **LB1 - Improving measurement of agitation in dementia incorporating IPA Agitation Working Group definition**  
*Zahinoor Ismail (1), Adelaide De Mauleon (2), Jeannie Leoutsakos (3), Cedric O’gorman (4), David Miller (5), Paul Rosenberg (3), Maria Soto Martin (2), Constantine Lyketsos (3)*  
(1) University of Calgary, Canada, (2) Centre Hospitalier Universitaire, France, (3) Johns Hopkins, United States, (4) Axsome, United States, (5) Signant Health, United States

3.00 p.m  **LB12 - MAPT Trial: 5-year follow-up results**  
*Bruno Vellas (1), Sophie Guyonet (1), Jacques Touchon (2), Christele Cantet (1), Sandrine Andrieu (1) And The Mapt Group*  
(1) Toulouse University Hospital, France, (2) Montpellier University Hospital, France

3.15 p.m  **LB13 - Item Response Theory Analysis of the Clinical Dementia Rating**  
*Yan Li (1), Chengjie Xiong (1), Andrew Aschenbrenner (1), Chih-Hung Chang (1), Virginia Buckles (1), Krista Moulder (1), Michael Weiner (2), Dan Mungas (3), Rachel Nosheny (2), Taylor Howell (2), John Morris (1)*  
(1) Washington University in St. Louis, United States, (2) University of California, San Francisco, United States, (3) University of California, Davis, United States

3.30 p.m  Coffee Break and poster sessions / Posters P1 to P110 Themes 1,2,3,4 - INDIGO Foyer

4.00 p.m  **SYMPOSIUM 3**  
*Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies*  
**Chairman: Bengt Winblad, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden**

**PRESENTER 1:** Dementias, who and how to treat and by what specialty . Addressing problem and current and potential future therapeutic practices  
*Charles DeCarli, MD, FAAN, FAHA, UC Davis, CA, USA*

**PRESENTER 2:** Fluid biomarkers that predict and project brain health  
*Henrik Zetterberg, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden*

**PRESENTER 3:** The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease  
*Ewelina Kulikowska, SVP Research and Development, Resverlogix Corporation, Calgary, Canada*

**PRESENTER 4:** Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease  
*Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA*

4.45 p.m  **ROUNDTABLE**  
*BACE Inhibition: What do we know and what do we need to know?*  
**Co-chairs: Maria Carrillo, Alzheimer’s Association, United States, Reisa Sperling, Brigham & Women’s Hospital, United States**

**PRESENTATION 1:** Improve synaptic dysfunction in association with BACE1 inhibition  
*Yan Riqiang, University of Connecticut, United States*
Thursday, DECEMBER 5

PRESENTATION 2: The Generation Program: Preliminary data on baseline characteristics of participants randomized in Generation Study 1 and Generation Study 2
Pierre N. TARIOT (1), Beth BOROWSKY (2), Fonda LIU (2), Marie-Emmanuelle RIVIERE (3), Marie-Laure ROUZADE-DOMINGUEZ (3), Laurie DUFF (2), Matt QUINN (2), Ingo SCHOLTEN (3), Jessica LANGBAUM (1), Angelika CAPUTO (3), Vissia VIGLIETTA (4), Eric REIMAN (1), Ana GRAF (3) - (1) Banner Alzheimer’s Institute, United States, (2) Novartis Pharmaceuticals, United States, (3) Novartis Pharma, Switzerland, (4) Amgen, Inc., United States

PRESENTATION 3: API Perspective what we would learn from the discontinuation phase
Eric REIMAN, Alzheimer’s Prevention Initiative, United States

PRESENTATION 4: A review of volumetric MRI changes in AD treatment trials and a framework for their interpretation
Adam Schwarz, Takeda, Cambridge, MA, USA

PRESENTATION 5: DIAN: Primary Prevention Discussion
Eric McDade, Washington University, United States

PRESENTATION 6: Modeling of verubecestat Ph3 PK/PD data against to amyloid PET
Julie Stone, Merck, USA

DISCUSSION:
1) Is there a lowest dose that could be efficacious, using modeling or preclinical models, i.e. not just to avoid side effects but to identify a therapeutic window?
2) To what could still be done non-clinically to understand if anything would have predicted the adverse effects
Michael F. Egan, M.D, Merck, USA, Michael Irizarry, Eisai, USA, John Sims, Eli Lilly & Co., USA, Craig Sherring, AstraZeneca, USA

5.45 p.m LATE BREAKING ORAL COMMUNICATIONS
Chairs: Audrey Gabelle, Jose Luis Molinuevo

5.45 p.m LB6 - Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease: a randomized, placebo-controlled, double-blind clinical trial
Gregory JICHA, Richard KRYSCIO, Brooke BEECH, Wangxia WANG, Bert LYNN, Frederick SCHMITT, Beth COY, Omar AL-JANABI, Erin ABNER, Peter NELSON - (1) University of Kentucky, United States

6.00 p.m LB7 - One-month oral treatment with PTI-125, a new drug candidate, reduces CSF and plasma biomarkers of Alzheimer’s disease
Lindsay BURNS (1), Hoau-Yan WANG (2), Zhe PEI (2), Carrie CROWLEY (2), Michael MARSMAN (2), Nadav FRIEDMANN (2) - (1) Cassava Sciences, Inc., United States, (2) City of New York School of Medicine, United States

6.15 p.m LB8 - Early changes in Alzheimer’s disease biomarkers show interplay between tau metabolism, inflammation, synaptic damage and neurodegeneration: results from the ALFA study
José Luis MOLINUEVO (1), Gemma SALVADO (1), Marta MILA (1), Kaj BLENNOW (2), H ZETTERBERG (3, 4, 5), Grégory OPERTO (1), Carles FALCÓN (1), R BATRLA (6), G KOLLMORGEN (7), Gonzalo SÁNCHEZ-BENAVIDES (1), Juan Domingo GISPERT (1), Marc SUAREZ-CALVET (1) - (1) Barcelonabeta Brain Research Center, Fundació Pasqual Maragall, Pompeu Fabra University, Spain, (2) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Sweden, (3) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Sweden, (4) Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, United Kingdom, (5) UK Dementia Research Institute at UCL, United Kingdom, (6) Roche Diagnostics International Ltd, Switzerland, (7) Roche Diagnostics GmbH, Germany

6.30 p.m LB9 - Blood plasma phospho-tau isoforms detect CNS change in Alzheimer’s disease
Nicolas BARTHÉLEMY, Kanta HORIE, Chihiro SATO, Randall BATEMAN - (1) Washington University School of Medicine, United States
Friday, DECEMBER 6

8.00 a.m  LATE BREAKING ORAL COMMUNICATIONS
Chairs: Andrew Stephens, Kenneth Rockwood

8.00 a.m  LB14 - A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and Mild and Moderate Alzheimer’s Disease
Lloyd Tran, Fern Vu, Brian Tran, Stephanie Neave
(1) NeuroActiva, Inc., United States

8.15 a.m  LB15 - The CHARIOT-PRO Substudy: Baseline Characteristics of the Fully Enrolled Cohort
Gerald Novak (1), Susan Baker (1), Chi Udoh-Momo (2), Geraint Price (2), Tam Watermeyer (3), Celeste Loots (2), Natalia Regliniska-Matveyev (3), Luc Bracoud (4), Craig Ritchie (3), Lefkos Middleton (2)
(1) Janssen R&D, United States, (2) Imperial College London, United Kingdom, (3) University of Edinburgh, United Kingdom, (4) Bioclinica, France

8.30 a.m  LB16 - Association between Neuraceq levels and [18F]PI-2620 Tau PET tracer accumulation in baseline scans of the elenbecestat MissionAD program
Andrew Stephens (1), Santi Bullich (1), Andre Mueller (1), Mathias Berndt (1), Susan De Santi (1), David Scott (2), Katarzyna Adamczuk (2), Joyce Suhy (2), June Kaplow (3), Monique Giroux (3), Stephen Krause (3), Julia Chang (3), Bruce Albala (3)
(1) Life Molecular Imaging, Germany, (2) Bioclinica, United States, (3) Eisai Inc, United States

8.45 a.m  LB17 - Exploring the patterns of cognitive symptoms tracked by caregivers and patients in online symptom profiles
Kenneth Rockwood (1,2), Taylor Dunn (2), Jovita Balcaitiene (3), Susan Howlett (1,2)
(1) Dalhousie University, Canada, (2) DGI Clinical, Canada, (3) Nutricia, Netherlands

9.00 a.m  ORAL COMMUNICATIONS SESSION
Chairs: Jason Hassenstab, Sandrine Andrieu

9.00 a.m  OC9 - Anchor- and Distribution-based methods to establish clinically meaningful score changes on the Clinical Dementia Rating Scale – Sum of Boxes in patients with prodromal Alzheimer’s Disease
Claire J. Lansdall (1), Lesley M. Butler (2), Geoff Kerchner (2), Fiona McDougall (2), Paul Delmar (2), Nathalie Pross (2), Shanshan Qin (3), Loni McLeod (3), Monika Baudler (2), Paulo Fontoura (2), Rachelle Doody (2,4)
(1) Roche Products Limited, United Kingdom, (2) F. Hoffmann-La Roche Ltd, Switzerland, (3) RTI Health Solutions, United States, (4) Genentech, Inc., United States

9.15 a.m  OC10 - Awareness of Genetic Risk in the Dominantly Inherited Alzheimer Network (DIAN)
Jason Hassenstab (1), Bryan D James (2), Andrew A Aschenbrenner (1), Eric M Mcdade (1), Guogiao Wang (1), Yen Ying Lim (3), Tammie L S Benzinger (1), Carlos Cruchaga (1), Alison Goate (4), Chengjie Xiong (1), Virginia Buckles (1), John C Morris (1), Randall J Bateman (1)
(1) Washington University in St. Louis, United States, (2) Rush University, United States, (3) The Florey Institute of Neuroscience and Mental Health, Australia, (4) Icahn School of Medicine at Mount Sinai, United States

9.30 a.m  OC11 - Alzheimer’s Prevention Initiative Generation Program: Update and Next Steps
Ana Graf (1), Beth Borowsky (2), Pierre Tariot (3), Fonda Liu (2), Marie-Emmanuelle Riviere (1), Marie-Laure Rouzade-Dominguez (1), Jessica Langbaum (3), Angelika Caputo (1), Vissia Viglietta (4), Eric Reiman (3)
(1) Novartis Pharma, Switzerland, (2) Novartis Pharmaceuticals, United States, (3) Banner Alzheimer’s Institute, United States, (4) Amgen Inc., United States

9.45 a.m  OC12 - Recruitment Strategies for the Generation Program AD Prevention Clinical Trials: Lessons from the Butler Hospital Memory & Aging Program
Jessica Alber (1), Louisa Thompson (2), Stephen Salloway (2), Ginamarie Tonini (3), Athenee Lee (2)
(1) University of Rhode Island, United States, (2) Brown University, United States, (3) Butler Hospital, United States

10.00 a.m  Coffee Break and poster sessions / Posters P111 to P195 Themes 5,6,7,8,9,10,11 - INDIGO Foyer
**Friday, DECEMBER 6**

**10.30 a.m**

**KEYNOTE 3**

*And now what? Where are we headed in AD drug development?*

*Introduction: Bruno Vellas*

**Paul Aisen, MD** - Director of the Alzheimer's Therapeutic Research Institute, Keck School of Medicine, USC, San Diego, CA, USA

**11.00 a.m**

**SYMPOSIUM 4**

*AMBAR (Alzheimer's Management By Albumin Replacement) Phase 2B/3 Trial: complete clinical, biomarker and neuroimaging results*

*Chairman: Jeffrey L. Cummings, MD, Sc.D, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, USA*

**PRESENTATION 1: AMBAR: design and apheresis procedures**

Zbigniew M. Szczepiorkowski, M.D., Ph.D., Dartmouth Hitchcock Medical Center, Lebanon, NH, USA

**PRESENTATION 2: AMBAR: global results**

Antonio Páez, M.D., Grifols Bioscience Research Group, Spain

**PRESENTATION 3: AMBAR: statistical discussion**

Suzanne Hendrix, Ph.D., Pentara Corporation, Salt Lake City, UT, USA

*Discussion. Questions & Answers*

Jeffrey L. Cummings, M.D., Sc.D., Mercè Boada, M.D., Ph.D., Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain, Oscar L. Lopez, M.D., Ph.D., University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Zbigniew M. Szczepiorkowski, M.D., Ph.D., Dartmouth Hitchcock Medical Center, Lebanon, NH, USA, Montserrat Costa, Ph.D., Grifols Bioscience Research Group, Barcelona, Spain, Bruno Vellas, M.D., Ph.D., Toulouse University Hospital, Toulouse, France, Suzanne Hendrix, Ph.D, Pentara Corporation, Salt Lake City, UT, USA, Antonio Páez, M.D., Grifols Bioscience Research Group, Barcelona, Spain

**11.45 a.m**

Lunch (for pre-registered attendees) and poster sessions / Posters P111 to P195 Themes 5,6,7,8,9,10,11 - INDIGO Foyer

**1.00 p.m**

**ORAL COMMUNICATIONS SESSION**

*Chairs: Sarah Walter, Gregory Klein*

**1.00 p.m**

**OC13 - Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab**

Gregory Klein (1), Paul Delmar (2), Geoffrey Kerchner (2), Carsten Hofmann (1), Danielle Abi-Saab (2), Smiljana Ristic (2), Andrew Davis (3), Nicola Voyle (3), Monika Baudler (2), Paolo Fontoura (2), Rachelle Doody (2, 4)

(1) Roche Pharma Research and Early Development, Switzerland, (2) Roche/Genentech Product Development, Switzerland, (3) Roche Products Ltd, United Kingdom, (4) Genentech, Inc., United States

**1.15 p.m**

**OC14 - A Phase 1 Study of ALODZ in Healthy Volunteers and Patients With Mild-To-Moderate Alzheimer’s Disease**

Robert Paul, Michael Ward, Omer Siddiqui, Spencer Madeline, Long Hua, King Robert, Schwabe Tina, Lu Shiao-Ping, Rosenthal Arnon - (1) Alector, LLC, United States

**1.30 p.m**

**OC15 - Predicting sporadic Alzheimer’s progression via inherited Alzheimer’s-informed machine learning**

Nicolai Franzmeier (1), Nikolaos Koutsouleris (2), Tammie Benzinger (3), Alison Goate (4), Celeste Karch (3), Anne Fagan (3), Marco Duering (1), Martin Dichgans (1), Johannes Levin (5), Brian Gordon (3), Yen Ying Lim (6), Colin Masters (6), Nick C Fox (7), Jasmeer Chhatwal (8), Stephen Salloway (9), Eric Mcclade (3), John Morris (10), Randall Bateman (10), Michael Ewers (1)

(1) Ludwig Maximilians University, Institute for Stroke and Dementia Research, Germany, (2) Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität LMU, Munich, Germany, (3) Knight Alzheimer’s Disease Research Center, Washington University in St. Louis, St. Louis, MO, United States, (4) Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, (5) Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany, (6) The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia, (7) Dementia Research Centre, University College London, Queen Square, London, United Kingdom, (8) Massachusetts General Hospital, Department of Neurology, Harvard Medical School, MA, United States, (9) Department of Neurology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States, (10) Department of Neurology, Washington University in St. Louis, St. Louis, MO, United States
1.45 p.m
OC16 - Continuously Acquired, Home-Based Digital Biomarkers of Activity and Function Are Related to Alzheimer’s Disease Neuropathology
Jeffrey Kaye, Nora Mattek, Hiroko Dodge, Nicole Sharma, Thomas Riley, Zachary Beattie, Randy Woltjer
(1) Oregon Health & Science University, United States

2.00 p.m
OC17 - The Alzheimer’s Clinical Trials Consortium Seeks Partners for Therapeutic Trials
Sarah Walter (1), Reisa Sperling (2), Ron Petersen (3), Laurie Ryan (4), Rema Raman (1), Jason Karlawish (5), Christopher Van Dyck (6), Paul Aisen (1)
(1) Alzheimer’s Therapeutic Research Institute (ATRI), University of Southern California, United States, (2) Brigham and Women’s Hospital, Harvard University, United States, (3) Mayo Clinic, United States, (4) National Institute on Aging, National Institutes of Health, United States, (5) University of Pennsylvania, United States, (6) Yale University, United States

2.15 p.m
OC18 - The EXERT Trial: Testing a Model for Effective Community-Based Exercise Intervention Delivery for Adults with MCI
Jeffrey Katula (1), Elizabeth Chmelo (1), Valerie Lawson (2), Heather Hodge (2), Cara Johnson (2), Barbara Nicklas (1), Rosemary Morrison (3), Sean Kipperman (3), Howard Feldman (3), Carl Cotman (3), Laura Baker (1)
(1) Wake Forest School of Medicine, United States, (2) YMCA of the USA, United States, (3) Alzheimer’s Disease Cooperative Study, University of California, San Diego, United States

2.30 p.m
OC19 - The effects of rasagiline upon cerebral glucose metabolism, cognition, and tau in patients with mild to moderate Alzheimer’s disease: Results of a Phase II clinical trial
Dawn Matthews (1), Aaron Ritter (2), Ronald Thomas (3), Randolph Andrews (1), Ana Lukic (1), Carolyn Revta (3), Babak Tousi (2), James Leverenz (2), Howard Fillit (4), Kate Zhong (2), Howard Feldman (3), Jeffrey Cummings (2)
(1) ADM Diagnostics Inc, United States, (2) Cleveland Clinic - Lou Ruvo Center for Brain Health, United States, (3) Alzheimer’s Disease Cooperative Study - University of California San Diego, United States, (4) Alzheimer’s Drug Discovery Foundation, United States

2.45 p.m
OC20 - Towards a florbetapir-based dual-biomarker screening strategy
Sergey Shcherbinin (1), Georgia Chao (2), Fanni Natanegara (1), Arnaud Charil (1), Jennifer Zimmer (1), Alette Wessels (1), Cynthia Evans (1), Albert Lo (1), Mark Mintun (1), John Sims (1)
(1) Eli Lilly and Company, United States, (2) Covance, United States

3.00 p.m
KEYNOTE 4
Next generation of multidomain lifestyle clinical trials: Design and implementation for proof of scientific concept and pragmatic sustainability
Introduction: Howard Feldman
Laura D. Baker, PhD - Associate Professor, Gerontology and Geriatric Medicine, Wake Forest School Medicine, Winston-Salem, NC, USA

3.30 p.m Coffee Break and poster sessions / Posters P111 to P195 Themes 5,6,7,8,9,10,11 - INDIGO Foyer

4.00 p.m
OC21 - FCSRT inclusion criteria support recruitment of a population with early Alzheimer’s disease likely to progress over 24 months: results from the CREAD trial
Kaycee Sink (1), Stevan Djakovic (1), Janice W. Smith (2), Jillian Smith (2), Nan Hu (1), Howard Mackey (1), Susanne Ostrowitzki (1), Rachelle Doody (1,3)
(1) Genentech, Inc., United States, (2) Roche Products Ltd, United Kingdom, (3) Product Development, F. Hoffmann-La Roche Ltd, Switzerland

4.15 p.m
OC22 - Assessing in Power in Phase II Proof-of-Concept Trials in Prodromal Alzheimer’s Disease
Michelle Nuño (1,2), Daniel Gillen (1,2), Joshua Grill (3,4,5)
(1) Department of Statistics, University of California, Irvine, United States, (2) Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (3) Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (4) Department of Psychiatry and Human Behavior, University of California, Irvine, United States, (5) Department of Neurobiology and Behavior, University of California, Irvine, United States
Friday, DECEMBER 6

4.30 p.m  OC23 - The Alzheimer’s disease THERapy with NEuroaid (ATHENE) Study: Assessing the Safety and Efficacy of Neuroaid II (MLC901) in patients with mild to moderate Alzheimer’s disease stable on Cholinesterase inhibitors or Memantine: A Randomized, double blind, placebo-controlled trial: BASELINE RESULTS
Christopher Chen (1), Purabi Reang Sharma (2), Boon Yeow Tan (3), Lu Qingshu (4), Kee Ling Teo (5), Narayanaswamy Venkatasubramanian (6)

4.45 p.m  OC24 - Phase 1 study of NDX-1017: safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and dementia patients
Hans Moebius (1), Xue Hua (1), Kevin Church (1), William Walker (1), Philippe Lhostis (2), Philippe Danjou (3), Geoffrey Viardot (2), Leen Kawas (1)
(1) Athira Pharma, Inc., United States, (2) Core Lab, Drug Evaluation and Pharmacology Research, Biotrial, France, (3) Phase 1 Unit, Drug Evaluation and Pharmacology Research, Biotrial, United States

5.00 p.m  LATE BREAKING ORAL COMMUNICATIONS
Chairs: Suzanne Hendrix, Mohammad Afshar

5.00 p.m  LB18 - APTUS-Aβ™. Measurement of plasma Aβ42/40 concentration ratios by mass spectrometry predicts brain amyloidosis in banked samples from multiple, diverse cohorts
Tim West, Kristopher Kirmess, Matthew Meyer, Mary Holubasch, Stephanie Knapik, Yan Hu, Philip Verghese, Erin Smith, Scott Harpstrite, Ilana Fogelman, Joel Braunstein, Kevin Yarasheski
(1) C2N Diagnostics, United States

5.15 p.m  LB19 - In vivo measurement of widespread synaptic loss in early Alzheimer’s disease with SV2A PET
Christopher Van Dyck, Adam Mecca, Ming-Kai Chen, Ryan O’dell, Mika Naganawa, Takuya Toyonaga, Tyler Godek, Joanna Harris, Hugh Bartlett, Wenzhen Zhao, Nabeel Nabulsi, Brent Vander Wyk, Pradeep Varma, Amy Arnsten, Yiyun Huang, Richard Carson
(1) Yale School of Medicine, United States

5.30 p.m  LB20 - Novel analytics framework for augmenting single-arm Phase 2a open label trials with Real-World external control data: Application to the Blarcamesine (ANAVEX®2-73) study in Alzheimer’s disease matched with propensity corrected patients from Alzheimer’s Disease Neuroimaging Initiative (ADNI) exploring treatment effect on cognition at Interim two-year (104-Week) timepoint
Mohammad Afshar (1), Coralie Williams (1), Nanthara Sritharan (1), Frederic Parmentier (1), Federico Goodsaid (2), Christopher Missling (3)
(1) Ariana Pharma, France, (2) Regulatory Pathfinders, United States, (3) Anavex, United States

5.45 p.m  LB21 - Should We Be Using Artificial Intelligence, Machine Learning, and Big Data Techniques to Improve Our Chances of Success in Alzheimer’s Clinical Research?
Newman Knowlton, Sam Dickson, Suzanne Hendrix
(1) Pentara Corporation, United States
Saturday, DECEMBER 7

8.00 a.m  LATE BREAKING ORAL COMMUNICATIONS
Chairs: Merce Boada, Jacques Touchon

8.00 a.m  LB22 - Cut points for cognitive decline using MMSE define baseline and longitudinal differences in both clinical and pathological Alzheimer's disease biomarkers
James Doecke (1), Marcela Cespedes (1), Cai Gillis (2), Nancy Maserejian (2), Pierrick Bourgeat (3), Chris Fowler (4), Victor Villemagne (5), Qiao-Xin Li (4), Steven Collins (4), Stephanie Rainey-Smith (6,7), Paul Maruff (4), Ralph Martins (6,8,9), David Ames (10), Colin Masters (4)
(1) Australian e-Health Research Centre, CSIRO, Australia, (2) Biogen, United States, (3) Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia, (4) The Florey Institute, The University of Melbourne, Australia, (5) Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Australia, (6) Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Australia, (7) Centre of Excellence for Alzheimer's disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Australia, (8) Department of Biomedical Sciences, Macquarie University, Australia, (9) School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia, (10) National Ageing Research Institute, Australia

8.15 a.m  LB23 - Using AI to Create Digital Twins to Accelerate Alzheimer's Disease Clinical Trials
Aaron Smith, Jonathan Walsh, Charles Fisher
(1) Unlearn.health, United States

8.30 a.m  ROUNDTABLE
Sex/gender consideration in clinical trials and potential improvements to clinical trial design
Merce Boada (1,2,3), Rachelle Doody (10), Antonella Santuccione, (4,7), Maria Teresa Ferretti MT (4,5,6), Cassandra Szoeke (8), Jennifer Ann Zimmer (9)
(1) Research Center and Memory Clinic. Fundació ACE, Institut Català de Neurociències Aplicades, (2) Universitat Internacional de Catalunya- Barcelona, Spain, (3) Networking Research Center on Neurodegenerative Disease (CIBERNED), Instituto de Salud Carlos III, Spain, (4) Women’s Brain Project Guntershausen, Switzerland, (5) Institute for Regenerative Medicine IREM, University of Zurich, Zurich, Switzerland, (6) Neuro Science Center Zurich (ZNZ), University of Zurich, Zurich, Switzerland, (7) Global Medical and Scientific Affairs, Roche Diagnostics International Ltd., Rotkreuz, Switzerland, (8) Women's Healthy Ageing Project, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia, (9) Eli Lilly and Company, Indianapolis, IN, USA, (10) Roche Pharmaceutical Company, Basel, Switzerland

9.15 a.m  ORAL COMMUNICATIONS SESSION
Chairs: Reisa Sperling, Michael Detke

9.15 a.m  OC25 - Regulation of giall cell activation and neurodegeneration by anti-semaphorin 4D antibody pepinemab (VX15/2503), a potential treatment for Alzheimer's and Huntington's Disease
Elizabeth Evans (1), Terrence Fisher (1), John Leonard (1), Alisha Reader (1), Vikas Mishra (1), Crystal Mallow (1), Leslie Balch (1), Alan Howell (1), Ernest Smith (1), Andrew Feigin (2), Maurice Zauderer (2)
(1) Vaccinex, United States, (2) Huntington Study Group, United States

9.30 a.m  OC26 - Therapeutic ultrasound as a treatment strategy for Alzheimer's disease - preclinical data (including Aducanumab) and clinical trial design
Jürgen Götz, Gerhard Leinenga, Rebecca Nisbet, Rachel De Las Heras
(1) The University of Queensland, Queensland Brain Institute, Australia

9.45 a.m  OC27 - Baseline Clinical and Biomarker Characteristics from a Phase 2 Trial of RO7105705 in Prodromal-to-Mild Alzheimer’s Disease (Tauriel)
Edmond Teng, Karen Pickthorn, Paul Manser, Kristin Wildsmith, Sandra Sanabria-Bohorquez, Michael Keeley
(1) Genentech, United States

10.00 a.m  OC28 - COR388, A Novel Gingipain Inhibitor, Decreases Fragmentation of ApoE in Alzheimer’s Disease Central Nervous System
Michael Detke (1), Debashish Raha (1), Florian Ermini (1), Casey Lynch (1), Leslie Holsinger (1), Shirin Arastu-Kapur (1), Dave Hennings (1), Ursula Haditsch (1), Sean Broce (1), Theresa Roth (1), Mai Nguyen (1), Mark Ryder (2), Ira Goodman (3), Stephen Thein (4), Stephen Dominy (1)
(1) Cortexyme, United States, (2) UCSF, United States, (3) Bioclinica, United States, (4) Pacific Research Network, United States
10.15 a.m Coffee Break and poster sessions / Posters P111 to P195 Themes 5,6,7,8,9,10,11 - INDIGO Foyer

10.45 a.m SYMPOSIUM 5
Alzheimer’s Disease in Down Syndrome: New Insights and Opportunities
Chairman: Michael Rafii, USC, San Diego, CA, USA

PRESENTATION 1: Cognitive markers of preclinical and prodromal Alzheimer’s disease in Down syndrome
Andre Strydom, King’s College London, London, UK

PRESENTATION 2: Neuroimaging biomarkers of AD in DS
Brad Christian, University of Wisconsin, Madison, WI, USA

PRESENTATION 3: Plasma and CSF biomarkers for the diagnosis of AD in DS
Juan Fortea, Hospital Saint Pau, Barcelona, Spain

11.30 a.m ORAL COMMUNICATIONS SESSION
Chairs: Carol Van Hulle, Gustavo Jimenez-Maggiora

11.30 a.m OC29 - Binding profiles of BAN2401 and aducanumab to different amyloid-beta species
Lars Lannfelt (1), Linda Söderberg (2), Hanna Laudon (2), Malin Johannesson (2), Charlotte Sahlin (2), Patrik Nygren (2), Christer Möller (2)
(1) Uppsala University, Sweden, (2) BioArctic, Sweden

11.45 a.m OC30 - Non-GLP Toxicity and Toxicokinetics Studies of P8, a Peptide Drug Candidate for the treatment of Alzheimer’s Disease
Nazneen Dewji (1), Michael Bleavins (2), Archie Thurston (3)
(1) Cenna Biosciences Inc., United States, (2) White Crow Innovation, LLC, United States, (3) Admesolutions Inc., United States

12.00 p.m OC31 - An exploratory examination of NeurotoolKit biomarkers across AD stages
Carol Van Hulle (1), Tobey Bethhauser (1), Erin Jonaitis (1), Richard Batra (2), Norbert Wild (2), Katherine Buck (3), Gwendlyn Kollmorgen (3), Ulf Andreasson (4), Henrik Zetterberg (4), Kaj Blennow (4)
(1) University of Wisconsin-Madison, United States, (2) Roche Diagnostics International Ltd, Switzerland, (3) Roche Diagnostics GmbH, Germany, (4) Uppsala University, Sweden

12.15 p.m Lunch (for pre-registered attendees) and Poster Sessions / Posters P111 to P195 Themes 5,6,7,8,9,10,11 - INDIGO Foyer

1.15 p.m OC32 - Improving Polygenic Risk Scores for Alzheimer’s Disease
Samuel P Dickson (1), Suzanne B Hendrix (1), Bruce L Brown (2), Perry G Ridge (2), Marci L Hardy (3), Allison M Mckeany (3), Steven B Booth (3), Ryan R Fortna (3), John S K Kauwe (2)
(1) Pentara Corporation, United States, (2) Brigham Young University, United States, (3) ADx Healthcare, United States

1.30 p.m OC33 - Evaluating mixed effects models for burst cognitive data in Alzheimer disease clinical trials
Guoqiao Wang (1), Yan Li (2), Andrew Aschenbrenner (2), Jason Hassenstab (2), Eric Mcdade (2), Jorge Llibre-Guerra (2), Randall Bateman (2), Chengjie Xiong (1)
(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States, (2) The Dominantly Inherited Alzheimer Network Trials Unit, Department of Neurology, Washington University School of Medicine, St. Louis, MO, United States

1.45 p.m OC34 - Safety, pharmacokinetics and pharmacodynamics of RDN-929: a potent and selective HDAC-CoREST complex inhibitor for the treatment of synaptopathies
J. Michael Ryan (1), Christine Voors-Pette (2), Christel Romeijn (2), Minh Vo (3), Magnus Ivarsson (1), Berkely A. Lynch (1), Antonella Pirone (1), Michael C. Hewitt (1), Nathan O. Fuller (1), Amy Dirico (1), Steven P. Sweeney (1)
(1) Rodin Therapeutics, United States, (2) OPS, Netherlands, (3) Certara, United States
Saturday, December 7

2.00 p.m. OC35 - A Phase 2 trial of GRF6019 in mild-to-moderate Alzheimer’s disease
Jonas Hannestad (1), Tiffanie Pederson (1), Whitney Chao (1), Katie Koborsi (1), Vicki Klutzaritz (1), Steven Braithwaite (1), Suzanne Hendrix (2), Karoly Nikolich (1)
(1) Alkahest, United States, (2) Pentara Corporation, United States

2.15 p.m. OC36 - HOPE4MCI Trial: Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101
Sharon Rosenzweig-Lipson (1), Russell Barton (1), Michela Gallagher (2), Richard Mohs (1)
(1) AgeneBio, Inc, United States, (2) Johns Hopkins University, United States

2.30 p.m. End of conference
POSTERS SESSION

Wednesday, December 4 and Thursday, December 5

1. Clinical trials: Methodology
   P1 to P36

2. Clinical trials: Results
   P37 to P52

3. Clinical trials: Imaging
   P53 to P72

4. Clinical trials: Biomarkers including plasma
   P73 to P110

Friday, December 6 and Saturday, December 7

5. Clinical trials: Cognitive and functional endpoints
   P111 to P131

6. Cognitive assessment and clinical trials
   P132 to P157

7. Behavioral disorders and clinical trials
   P158 to P164

8. Health Economics and clinical trials
   P165

9. Epidemiology and clinical trials
   P166 to P171

10. Clinical Trials: Animals Models
    P172 to P177

11. New therapies and clinical trials
    P178 to P195
THEME 1
Clinical trials methodology

P1 Underrepresented Elders in The Brain Health Registry: US Representativeness and Registry Behavior
Miriam ASHFORD (1,2), Joseph EICHENBAUM (1,2,3), Irzah WILLIAMS (1,2,3), Juliet FOCKLER (2,3), Monica CAMACHO (1,2), Aaron ULBRICH (2,3), Derek FLENNIKEN (1,2), Diana TRURAN (1,2), R. Scott MACKIN (2,4), Michael W. WEINER (1,2,3), Rachel L. NOSHENY (2,4)
(1) Northern California Institute for Research and Education (NCIRE), United States, (2) Department of Veterans Affairs Medical Center, Center for Imaging and Neurodegenerative Diseases, United States, (3) Department of Radiology and Biomedical Imaging, University of California, United States, (4) Department of Psychiatry, University of California San Francisco, United States

P2 A Phase 3 - Efficacy and Safety Study Protocol of Tranecnucin (NA-831) in Participants Who Are Asymptomatic at Risk for Developing Alzheimer’s Dementia (PREVENTION)
Lloyd TRAN, Fern VU, Stephanie NEAVE, Brian TRAN
(1) NeuroActiva, Inc., United States

P3 Using Network Analysis and Machine Learning Methods to Evaluate the Efficacy of Lemborexant in Patients with Irregular Sleep Wake Rhythm Disorder and Alzheimer’s Disease Dementia
Nusrat Rabbee, PhD (1), Margaret Moline, PhD (1), Shobha Dhadda, PhD (1), Manuel Kemethofer, MSc (2), Naoki Kubota, MPHarm (3)
(1) Eisai, Inc., Woodcliff Lake - USA, (2) The Siesta Group, Vienna - Austria, (3) Eisai Co. Ltd., Tokyo - Japan

P4 Medicare Advantage – Impact of New Memory Fitness Benefit and Reimbursement Structure to Increase Referrals to Alzheimer’s Disease Clinical Trials
John DWYER, Cyndy CORDELL
(1) The Global Alzheimer’s Platform (GAP) Foundation, United States

P5 Suitability of EPAD Longitudinal Cohort Study (EPAD LCS) population from memory clinics for preventive clinical trials
Isabelle CARRIE (1), Pierre Jean OUSET (1,2,3), Delphine PENNETIER (1), Julien DELHIEU (1,2,3), Nathalie SASTRE HENGAN (1), Françoise LALA (1), Bruno VELLAS (1,2,3)
(1) Gerontopole, Toulouse University Hospital, France, (2) INSERM Unit 1027, France, (3) Toulouse University III, France

P6 A 48-Week Phase 3 Clinical Trial Method to Evaluate the Efficacy and Safety of NA-831] in Subjects With Early Alzheimer’s Disease
Lloyd TRAN, Fern VU, Brian TRAN, Stephanie NEAVE
(1) NeuroActiva, Inc., United States

P7 Diversity & Inclusion in Alzheimer’s Disease Clinical Trials Workforce: a survey to assess baseline membership and climate in the Alzheimer’s Clinical Trials Consortium (ACTIC)
Rema RAMAN (1), Amanda SMITH (2), Gustavo JIMENEZ-MAGGIORA (1), Karin ERNSTROM (1), Jia-Shing SO (1), Marian WONG (1), Paul AISEN (1), Reisa SPERLING (3), Neelum AGGARWAL (4)
(1) Alzheimer’s Therapeutic Research Institute, University of Southern California, United States, (2) USF Health Byrd Alzheimer’s Institute & Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, United States, (3) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, United States, (4) Rush Alzheimer Disease Center & Department of Neurological Sciences, United States

P8 The impact of patient selection strategies on clinical trial power
Kaanan SHAH (1,2), Michael DONOHUE (3), Jared CARA (1), Lon SCHNEIDER (3), Tom BEACH (1), Julie COLLENS (1)
(1) Vivid Genomics, United States, (2) Banner Sun Health Research Institute, United States, (3) University of Southern California, United States

P9 Physical Activity and Alzheimer’s Disease - 2: Clinical Trial Protocol
Jennifer ETNIER (1), Laurie WIDEMAN (1), William KARPER (1), Jeffrey LABBAN (1), Christopher WAHLHEIM (1), Tomeka WILLIAMS (2), Shonda MOBLEY (1), Alexis SLUTSKY (1,3), Kyong Shin PARK (1), Nathaniel BERRY (1)
(1) University of North Carolina at Greensboro, United States, (2) East Carolina University, United States, (3) UNC Greensboro Gateway MRI Center, United States

P10 Reproducibility and Replicability of Digital Biomarkers for Reducing Sample Sizes in Preclinical Alzheimer Trials
Chao-Yi WU (1,2), Hiroko DODGE (1,2,3), Zachary BEATTIE (1,2), Nora MAITEK (1,2), Jeffrey KAYE (1,2)
(1) Department of Neurology, Oregon Health & Science University, United States, (2) Oregon Center for Aging and Technology (ORCATECH), Oregon Health & Science University, United States, (3) Michigan Alzheimer’s Disease Center, Department of Neurology, University of Michigan, United States

P11 Novel analytics framework for augmenting single-arm Phase 2a open label trials with Real-World external control data: Application to the Blarcamesine [ANADEX®2-73] study in Alzheimer’s disease matched with propensity corrected patients from Alzheimer’s Disease Neuroimaging Initiative (ADNI) exploring treatment effect on cognition at Interim two-year [104-Week] analysis
Mohammad AFSHAR (1), Coralie WILLIAMS (1), Nanthara SRITHARAN (1), Frederic PARMENTIER (1), Federico GOODSAID (2), Christopher MISSLING (3)
(1) Ariana Pharma, France, (2) Regulatory Pathfinders, United States, (3) ANAVEX, United States

P12 Using Direct-to-Consumer Genetic Testing Results in Alzheimer’s Disease Clinical Trial Recruitment
Mary RYAN (1,2), Chelsea COX (3), Joshua GRILL (4,5,3), Daniel GILLEN (1)
(1) Department of Statistics, University of California, Irvine, United States, (2) Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (3) Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (4) Department of Psychiatry & Human Behavior, University of California, Irvine, United States, (5) Department of Neurobiology & Behavior, University of California, Irvine, United States
P13 Differences in Willingness to Participate in Clinical Research According to Diagnostic Groups
Lovingly PARK, Svetlana SEMENOVA, Gaby ALARCON, Zyanya MENDOZA, Lydia MORRIS, Lev GERTSIK, Sophie LEE, Stan JHEE
(1) Parexel International, United States

P14 Gene- and Age-Informed Screening for Preclinical Alzheimer’s Disease Trials
Barbara SPENCER, Leonardino DIGMA, Robin JENNINGS, James BREWER
(1) UC San Diego, United States

P15 ECT-AD Study Design: A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Management of Treatment-Refractory Agitation in Alzheimer’s Dementia
Maria LAPIID (1), Brent FORESTER (2), Adriana HERMIDA (3), Louis NYKAMP (4), Martina MUELLER (5), Rebecca KNAPP (5), Bruce SUTOR (1), Emily JOHNSON (1), Monica WALTON (1), Steve SEINER (2), David HARPER (2), Emily KILPATRICK (2), Hannah HEINTZ (2), William MCDONALD (3), Patricio RIVA POSSE (3), Rebecca SEIDEMANN (3), Amitha DHINGRA (3), Jack MAHDAVIAN (4), Sohag SANGHANI (6), Georgios PETRIDES (6)
(1) Mayo Clinic, United States, (2) McLean Hospital, United States, (3) Emory University, United States, (4) Pine Rest Christian Mental Health Center, United States, (5) Medical University of South Carolina, United States, (6) Zucker Hillside Hospital/Northwell Health, United States

P16 Generating synthetic control subjects using machine learning for Alzheimer’s Disease clinical trials
Aaron SMITH, Charles FISHER, Jonathan WALSH
(1) UnlearnHealth, United States

P17 A paradigm shift in AD clinical trial design: Sequential, temporal, overlapping combination therapy from the cognitively normal at risk population to preclinical disease stage and beyond
Jennifer MURPHY (1), Claudine BRISARD (2), Joanne BELL (1)
(1) SyneosHealth.com, United States, (2) SyneosHealth.com, France

P18 Development of a machine learning algorithm to classify dementia stage based on symptoms reported online
Kenneth ROCKWOOD (1, 2), Aqib SHEHZAD (2), Justin STANLEY (2), Taylor DUNN (2), Susan HOWLETT (1, 2), Arnold MITNITSKI (1, 2), Chere CHAPMAN (2)
(1) Dalhousie University, Canada, (2) Digi Clinical, Canada

P19 A frailty index based on routinely collected laboratory safety data is associated with cognitive decline in clinical trials for anti-dementia drugs
Kenneth ROCKWOOD (1, 2), Taylor DUNN (2), Susan HOWLETT (1, 2), Justin STANLEY (2), Arnold MITNITSKI (1, 2), Chere CHAPMAN (2)
(1) Dalhousie University, Canada, (2) Digi Clinical, Canada

P20 Comparison of the FCSRT and RBANS in screening early Alzheimer’s disease patients for clinical trials
Edmond TENG, Stevan DJAKOVIC, Paul MANSER, Nan HU, Heavenly SWENDSEN, Kaycee SINK
(1) Genentech, United States

P21 Primary Analysis Model for Sporadic Alzheimer Disease: Univariate model for the composite score or Multivariate model for all the component scores?
Yan LI (1), Guoqiao WANG (1), Andrew ASCHENBRENNER (1), Jason HASSENBAT (1), Eric MCDADE (1), Jorge LLIBRE-GUERRA (1), Scott BERRY (2), Randall BATEMAN (1), Chengjie XIONG (1)
(1) Washington University in St. Louis, United States, (2) Berry Consultants, LLC, United States

P22 Study Partner Type and Dropout in Alzheimer’s Disease Registration Clinical Trials
Olivia M. BERNSTEIN (1), Joshua D. GRILL (2), Daniel L. GILLEN (1)
(1) Department of Statistics, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (2) Departments of Psychiatry & Human Behavior and Neurology & Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States

P23 A Phase II study evaluating efficacy and safety of oral BI 425809 in patients with cognitive impairment due to Alzheimer’s disease dementia
Glen WUNDERLICH (1), Frank JESSEN (2), Miguel GARCIA JR. (3), Zuzana BLAHOVA (4)
(1) Boehringer Ingelheim, Canada, (2) Klinik und Poliklinik für Psychiatrie und Psychotherapie, Uniklinik Köln, Germany, (3) Boehringer Ingelheim Pharmaceuticals Inc, United States, (4) Boehringer Ingelheim RCV GmbH & Co KG, Austria

Thomas DOHERTY (1), Jennifer MURPHY (2), Robert SMITH (3), Julie MARSH (4), Luke KOSCHALKA (5), Mairelys MARTINEZ (2), Michelle GEE (6), Bruce ALBALA (7)
(1) Department of Statistics, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (2) Department of Psychiatry & Human Behavior and Neurology & Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (3) Worldwide Clinical Trials, France, (4) Medavante, United States, (5) Syneos Health, Spain, (6) Eisai Ltd, United Kingdom, (7) Eisai Inc., United States

P25 Quantifying Impact of Enrichment in Alzheimer’s Disease Trials when Pre-Post Models are Utilized
Navneet HAKHU (1), Daniel GILLEN (1, 2), Joshua GRILL (1, 3)
(1) Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, United States, (2) Department of Statistics, University of California, Irvine, United States, (3) Department of Psychiatry and Human Behavior, University of California, Irvine, United States
THEME 1
Clinical trials methodology

P26 Validation of Alzheimer's Biomarkers: Amyloid beta 1-40 and Phosphorylated Tau in Cerebrospinal fluid (CSF) by Automated CLEIA on Fujirebio's LumiPulse Platform
Satya Nandana NARLA (1), Amanda DIDER (1), Florent FLORENT (2)
(1) Covance, United States, (2) Covance, Switzerland

P27 A cohort study to identify predictors for the clinical progression to mild cognitive impairment or dementia from subjective cognitive decline
Seonghee HO, Dong Won YANG
(1) The Catholic University of Korea, Seoul St. Mary's Hospital, Korea, Republic of

P28 Consistence in assaying plasma amyloid and Tau protein using two different protocols of preparing plasma samples via immunomagnetic reduction
W.P. CHEN (1), Shieh-Yueh YANG (2,1), Ming-Jang CHIU (3)
(1) MagQu LLC, United States, (2) Covance, United States, (3) National Taiwan University Hospital, Taiwan, Republic of China

P29 Dense Longitudinal Molecular Data for Turbocharging Clinical Trials
Jared ROACH (1), Junko HARAHARA (2), Jennifer LOVEJOY (1), Deborah FRIDMAN (2), Laura HEIM (2), Molly RAPOZO (1), Laura HEATH (1), Cory FUNK (1), Maria FISCHER (1), Leroy HOOD (1), Nathan PRICE (1), Michael BRANT ZAWADSKI (2), William SHANKLE (2)
(1) Institute for Systems Biology, United States, (2) Hoag Memorial Hospital Presbyterian, United States

P30 Study Design for Preventing Alzheimer’s with Cognitive Training: The PACT Trial
David MORGAN (1), Aryn HARRISON-BUSH (2), Alisa HOUSEKNECHT (2), Jennifer O’BRIEN (2), Jerri EDWARDS (2)
(1) Michigan State University, United States, (2) University of South Florida, United States

P31 Feasibility of Remote Collection of Genetic Material from Participants Enrolled in an Internet-Based Registry
Winnie KWANG (1,2), Juliet FOCKET (1,2), Derek FLENNIKEN (1,2), Joshua HWANG (1,2), Diana TRURAN (1), R. Scott MACKIN (1,3), Ruth O’HARA (4), Joachim HALLMAYER (4), Jerome YESAVAGE (4), Michael WEINER (2,1), Rachel NOSHENY (1,3)
(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, United States, (2) University of California, San Francisco Department of Radiology and Biomedical Imaging, United States, (3) University of California, San Francisco Department of Psychiatry, United States, (4) Stanford University Department of Psychiatry and Behavioral Sciences, United States

P32 Proposed methods for disclosing beta-amyloid status to cognitively unimpaired late-middle aged adults
Claire ERICKSON, Nathaniel CHIN, Lindsay CLARK, Sterling JOHNSON
(1) University of Wisconsin-Madison, United States

P33 Don’t Forget This! The patient in your study may be in another country
Thomas SHIOVITZ, Brittany STEINMILLER, Chelsea STEINMETZ, Sandra PEREZ
(1) CTdatabase, LLC, United States

P34 Data-Driven Participant Recruitment: Findings from the Alzheimer’s Disease Neuroimaging Initiative 3
Chanissa BARGER (1), Juliet FOCKET (1), Winnie KWANG (2), Shelley MOORE (1), Derek FLENNIKEN (2), Aaron ULBRICHT (2), Paul AISEN (1), Michael WEINER (2)
(1) USC Alzheimer’s Therapeutic Research Institute, United States, (2) UCSF Department of Radiology and Biomedical Imaging & Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, United States

P35 Learning from failed trials: virtual patient analysis of Aducanumab trial using a Quantitative Systems Pharmacology approach
Hugo GEERTS, Athan SPIROS
(1) In Silico Biosciences, United States

P36 A seamless phase 2a-2b randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of PQ912 in patients with early Alzheimer’s disease: design and methods
Howard FELDMAN (1), Karen MESSER (1), Frank WEBER (2), Kirsten ERICKSON (1), Branko HUISA (1), Timlan OLTERSDORF (1), Diane JACOBS (1), David SALMON (1), Carolyn REVTA (1), Suzanne BRUINS (2), Doug GALASKO (1), Oscar LOPEZ (3), Mary QUICENO (4), Murray RASKIND (5), Marwan SABBAGH (6), Raymond Scott TURNER (7)
(1) Alzheimer’s Disease Cooperative Study, University of California at San Diego, United States, (2) Probiodrug AG, Germany, (3) University of Pittsburgh Medical Center, United States, (4) University of North Texas Health Science Center, United States, (5) University of Washington, United States, (6) Cleveland Clinic Lou Ruvo Center for Brain Health, United States, (7) Georgetown University, United States
P37 Masupirdine (SUVN-502) in combination with donepezil and memantine in patients with moderate Alzheimer’s disease: Exploratory subgroup analyses of memantine regimen, concentrations and duration of treatment

Alirea ATRI (1), Jeffrey CUMMINGS (2), Ramakrishna NIROGI (3), Vinod GOYAL (3), Gopi BHAYAPUNENI (3), Pradeep JAYARAJAN (3), Venkat JASTI (3)
(1) Banner Sun Health Research Institute, Banner Alzheimer’s Institute, Banner Health; Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, United States, (2) Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States, (3) Suven Life Sciences, India

P38 Potential benefits of Masupirdine (SUVN-502) on behavioral and psychological symptoms in patients with moderate Alzheimer’s Disease

Jeffrey CUMMINGS (1), Ramakrishna NIROGI (2), Pradeep JAYARAJAN (2), Anil SHINDE (2), Venkat JASTI (2)
(1) Department of Brain Health, School of Integrated Health Sciences, University of Nevada; Cleveland Clinic Lou Ruvo Center for Brain Health, United States, (2) Suven Life Sciences, India

P40 Reversal of Alzheimer’s Memory Impairment by Transcranial Electromagnetic Treatment: Associated A-beta and Tau Changes in CSF/Blood and Brain Imaging Benefits

Gary ARENDASH (1), Chuanhai CAO (2), Haimab ABULABAN (3), Rob BARANOWSKI (4), Gary WISNIEWSKI (5), Lino BERCERRA (5), Ross ANDEL (6), John A RINGTON (7), Amanda SMITH (3)
(1) NeuroEM Therapeutics, Inc., United States, (2) College of Pharmacy, University of South Florida, United States, (3) University of South Florida Health/Byrd Alzheimer’s Institute, United States, (4) Left Coast Engineering, United States, (5) Invicro, United States, (6) School of Aging Studies, University of South Florida, United States, (7) University Diagnostic Institute, United States

P41 A 48-week, observational, longitudinal multicenter study on the effectiveness of 9.5 mg/24 h (10 cm2) rivastigmine in patients with mild to moderate dementia of the Alzheimer’s type

Chiuang Chih CHANG
(1) Kaohsiung Chang Gung Memorial Hospital, Taiwan, Republic of China

P47 Concentration-dependent reduction in clinical decline and brain atrophy in a Phase 3 trial of leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) in behavioural variant frontotemporal dementia

Christopher M KIPPS (1), Helen C SHIELLS (2), Bjorn O SCHELTER (2, 3), Serge GAUTHIER (4), Claude WISCHIK (2, 3)
(1) University Hospital, United Kingdom, (2) TauRx Therapeutics Ltd, United Kingdom, (3) University of Aberdeen, United Kingdom, (4) McGill Centre for Studies in Aging, Canada

P48 Reduction of clinical decline and brain atrophy in mild to moderate Alzheimer’s disease is concentration-dependent for leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) as monotherapy and as add-on therapy in two Phase 3 clinical trials

Bjorn O SCHELTER (1, 2), Helen C SHIELLS (1), Serge GAUTHIER (3), Christopher M RUBINO (4), Claude WISCHIK (1, 2)
(1) TauRx Therapeutics Ltd, United Kingdom, (2) University of Aberdeen, United Kingdom, (3) McGill Centre for Studies in Aging, Canada, (4) Institute of Clinical Pharmacodynamics, United States
THEME 2
Clinical trials results

**P49** The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study in Japan: Report of Screening Data Results
Takeshi IWATSUBO (1), Kazushi SUZUKI (1), Ryoko IHARA (1), Chie SAKANAKA (1), Yumi UMEDA-KAMEYAMA (1), Shinya ISHII (1), Kenji KIRIHARA (1), Atsushi IWATA (1), Chung-Kai SUN (2), Michael DONOHUE (2), Paul AISEN (2), Reisa SPERLING (3)
(1) The University of Tokyo Hospital, Japan, (2) Alzheimer’s Therapeutic Research Institute, United States, (3) Brigham and Women’s Hospital, United States

**P50** Effect of intensive cognitive intervention in mid Alzheimer’s disease: a pilot study
Soo Hyun JOO, Chang Uk LEE, Dong Woo KANG
(1) Seoul St. Mary’s hospital, Korea, Republic of

**P51** Is amyloid still a valid target for AD drug development? A meta-analysis of solanezumab mild AD dementia studies
Karen HOLDRIDGE, Roy YAARI, Scott ANDERSEN, John SIMS
(1) Eli Lilly and Company, United States

**P52** Lower serum calcium as a potentially associated factor for conversion of mild cognitive impairment to early Alzheimer’s disease in Japanese Alzheimer’s disease Neuroimaging Initiatives
Atsushi IWATA, Sato KENICHIRO, Ihara RYOKO, Suzuki KAZUSHI, Iwatsubo TAKESHI
(1) The University of Tokyo, Japan

THEME 3
Clinical trials imaging

**P53** Entorhinal Cortical Tau Accumulation is Inversely Associated with Hippocampal Synaptic Density in Older Individuals with Normal Cognition and Early Alzheimer’s Disease
Christopher VAN DYCK, Adam MECCA, Ming-Kai CHEN, Mika NAGANAWA, Takuya TOYONAGA, Tyler GODEK, Joanna HARRIS, Hugh BARTLETT, Jean-Dominique GALLEZOT, Nabeel NABULSI, Yiyun HUANG, Amy ARNSTEN, Richard CARSON
(1) Yale School of Medicine, United States

**P54** Distinguishing Alzheimer’s Disease with ventriculomegaly from Normal Pressure Hydrocephalus using MRI biomarkers
Minkyung KIM, Jun-Hyung LEE, Sang Hyung LEE
(1) Seoul National University, Medical College, Korea, Republic of

**P55** Diagnostic accuracy of whole brain cortical DTI changes measured in Alzheimer’s disease
Steven CHANCE (1), Mario TORISO (1), Marco BOZZALI (2), Omar EHSAN (1), Giovanna ZAMBONI (3), Mark JENKINSON (4)
(1) Oxford Brain Diagnostics, United Kingdom, (2) Santa Lucia Foundation, Italy, (3) Università di Modena e Reggio Emilia, Italy, (4) University of Oxford, United Kingdom

**P56** One-year longitudinal change of 18F-R0948 PET among cognitively unimpaired and patients with MCI or dementia in the BioFINDER2 study
Gregory KLEIN (1), Antoine LEUZY (2), Ruben SMITH (2), Sebastian PALMOVIST (2), Niklas MATTSSON (2), Danielle VAN WESTEN (2), Olof STRANDBERG (2), Jonas JÖGI (2), Tomas OHLSSON (2), Edilio BORRONI (1), Preciosa COLOMA (3), Erik STROMRUD (2), Oskar HANSSON (2)
(1) Roche Pharma Research and Early Development, Switzerland, (2) Clinical Memory Research Unit, Department of Clinical Sciences, Sweden, (3) Roche Pharma Development Personalized Health Care, Switzerland

**P57** Significant change of EEG biomarker in Parkinson’s disease with MCI after 1year of donepezil intake
Seung Wan KANG (1, 2), Seon Myeong KIM (1), Seok Min KIM (1), Dong Won KANG (1), Hannah LEE (1), Ukeob PARK (1), Suk Yun KANG (3), Young Ho SOHN (4), Phil Hyu LEE (4), Kyoung Won BAIK (4)
(1) MediSync Inc, Korea, Republic of, (2) Data Center for Korean EEG, College of Nursing, Seoul National University, Korea, Republic of, (3) Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Korea, Republic of, (4) Department of Neurology, Yonsei University College of Medicine, Korea, Republic of

**P58** qEEG changes in mild cognitive impairment with choline alphoscerate
Young Chul YOUN (1), Seung-Wan KANG (2)
(1) Dept. of Neurology, Chung-Ang Univ. Hospital, Korea, Republic of, (2) Data Center for Korean EEG, College of Nursing, Seoul National University, Korea, Republic of

**P59** APOE4/4 Subjects with Early Alzheimer’s Disease Show Accelerated Loss of Cortical Thickness and Cognitive Decline Compared to APOE3/3 Subjects
Susan ABUSHABRA, John HEY
(1) Alzheon Inc, United States
THEME 4
Clinical trials biomarkers

P73
Low testosterone levels relate to higher cerebrospinal p-tau levels: implications for sex differences in pathological tau
Erin SUNDERMANN, Xu CHEN, Matthew PANIZZON, Douglas GALASKO, Sarah BANKS
(1) University of California, San Diego, United States

P74
Association between serum markers of intestinal permeability and CSF biomarkers of Alzheimer’s disease and neurodegeneration
Margo HESTON (1, 2), Nicholas VOGL (1), Jack HUNT (1), Tyler ULLAND (3), Sanjay ASTHANA (1, 4), Sterling JOHNSON (1, 5, 4), Cynthia CARLSSON (1, 5, 4), Kaj BLENNOW (6), Henrik ZETTERBERG (7, 6, 8), Federic REY (9), Barbara BENDJIN (1), Nathaniel CHIN (1)
(1) Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, United States, (2) Cellular and Molecular Pathology, Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, United States, (3) University of Wisconsin School of Medicine and Public Health, United States, (4) Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, United States, (5) Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, United States, (6) Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sweden, (7) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Sweden, (8) University College London, United Kingdom, (9) University of Wisconsin-Madison Department of Bacteriology, United States

P75
Prediction of amyloid pathology by the plasma Aβ(1-42)/Aβ(1-40) ratio measured with fully automated immunoassay system [HISCL™ series]
Kazuto YAMASHITA (1), Takehiro HASEGAWA (1), Takuya INO (1), Masahiro MIURA (1), Toshihiro WATANABE (1), Shunsuke WATANABE (1), Shigeki IWANAGA (1), Amane HARADA (1), David VERBEL (2), Shobha DHADDIA (2), Hiroyuki AMINO (3), Mitsuhiro INO (3), Akihiko KOYAMA (2), Takehiko MIYAGAWA (3), Tomokazu YOSHIDA (1)
(1) Sysmex Corporation, Japan, (2) Eisai Inc., United States, (3) Eisai Co. Ltd., Japan

P76
Assessing Aβ clearance aided by mass spectrometry
Silje TORSETNES (1, 2), Marianne WETTERGREEN (2, 1), Erik CHRISTENSEN (3), Tormod FLADBY (1, 4)
(1) Department of Neurology, Akershus University Hospital, Norway, (2) Clinical Molecular Biology (EpiGen), Medical Division, Akershus University Hospital and University of Oslo, Norway, (3) Pre Diagnostics AS, Norway, (4) Institute of Clinical Medicine, Campus Ahus, University of Oslo, Norway

P77
A new blood-based biomarker of Aβ clearance – the monocuete Aβ mid-domain assay
Marianne WETTERGREEN (1, 2), Silje B TORSETNES (1), Berglind GISLADOTTIR (1), Erik CHRISTENSEN (3), Tormod FLADBY (1, 4)
(1) Department of Neurology, Akershus University Hospital, Norway, (2) Clinical Molecular Biology (EpiGen), Medical Division, Akershus University Hospital and University of Oslo, Norway, (3) Pre Diagnostics AS, Norway, (4) Institute of Clinical Medicine, Campus Ahus, University of Oslo, Norway

P78
Design of an Alzheimer’s Disease Specific SNP Array for Driving Polygenic Risk Scoring Algorithms
Richard PITHER (1), Alex GIBSON (1), Paula DAUNT (1), Greg DAVIDSON (2), Olusegun OSHOTA (1), Julie WILLIAMS (3), Valentina ESCOTT-PRICE (3), Rebecca SIMS (3), Efthysia BELLOU (3), John HARDY (4), Maryam SHOAI (4), Zsuzsanna NAGY (5)
(1) Cytox Ltd, United Kingdom, (2) Ledcourt Associates, United Kingdom, (3) University of Cardiff, United Kingdom, (4) University College London, United Kingdom, (5) University of Birmingham, United Kingdom

P79
Performance of a high-throughput plasma amyloid assay for diagnosis of Alzheimer’s disease
Oliver PETERS (1), Insa FEINKOHL (2), Carola SCHIPKE (3), Jochen KRUPPA (1), Georg WINTERER (1), Tobias PISCHON (2), Isabella HEUSER (1)
(1) CHDR, Netherlands, (2) MDC, Germany, (3) Predemtec, Germany

P80
Identifying healthy elderly subjects with Alzheimer pathology more efficiently for clinical trial participation
Samantha PRINS, Ahnjiil ZHUPARRIS, Ellen ‘T HART, Dimitrios ZIAGKOS, Geert Jan GROENEVELD
(1) CHDR, Netherlands

P81
Clinical utility of plasma amyloid beta measurements by immunoaffinity enrichment and LC-MS/MS
Shunsuke WATANABE (1), Takuya INO (1), Kazuto YAMASHITA (1), Eiya TAMADA (1), Takehiro HASEGAWA (1), Kazuya MATSUMOTO (1), Shigeki IWANAGA (1), Amane HARADA (1), Kousuke SUTO (1), Hiroyuki AMINO (2), Mitsuhiro INO (2), Takehiko MIYAGAWA (2), Tomokazu YOSHIDA (1)
(1) Sysmex Corporation, Japan, (2) Eisai Co. Ltd., Japan

P82
RetiSpec Technology used for Patient Recruitment
Stephen THEIN (1), Jamie JIRIK (2)
(1) Medical Director, United States, (2) Recruitment & Marketing Manager, United States

P83
Amyloid-targeting, Blood-based Biomarker of Alzheimer’s disease: Staging and Classification
Sangyun KIM (1), Young Chul YOUN (2)
(1) Seoul National University Bundang H, Korea, Republic of, (2) ChungAng University Hospital, Korea, Republic of
**POSTERS PRESENTATION**

**P84** Gut Microbiota and Response to Blarcamesine (ANAVEX2-73) in Alzheimer’s Disease Patients: Abundance of Lachnospiraceae and Enterobacteriaceae Families as Potential Biomarker of Response from a 2-Year Study Interim Clinical Data Analysis using KEM Artificial Intelligence
Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2)
(1) Ariana Pharma, France, (2) Anavex, United States

**P85** Plasma neurofilament light is a marker of incident cognitive decline associated with Mild Behavioral Impairment – lessons for clinical trial recruitment
Zahinoor ISMAIL, James NAUDE, Sascha GILL, Sophie HU, Alexander MCGIRR, Nils FORKERT, Oury MONCHI, Peter STYS, Eric SMITH
(1) University of Calgary, Canada

**P86** APOE-ε4 carrier identification, results from the Generation Program at Glasgow Memory Clinic
Kirsty HENDRY, Jennifer LYNCH, Susan WILLIAMSON, Emma LEE, Lorna WALLACE, Alison CRANMER, Laura MAIN, Fraser INGLIS
(1) Glasgow Memory Clinic, United Kingdom

**P87** The Generation Program Alzheimer’s Disease prevention clinical trials - Final results of recruitment strategy for APOE4 carriers at Glasgow Memory Clinic
Kirsty HENDRY, Jennifer LYNCH, Susan WILLIAMSON, Emma LEE, Lorna WALLACE, Alison CRANMER, Laura MAIN, Fraser INGLIS
(1) Glasgow Memory Clinic, United Kingdom

**P88** Association of APOE ε2 Genotype with Neuroprotection in Alzheimer’s and Non-Alzheimer’s Neuropathologies: A Transdiagnostic Study of 1557 Brains in the NACC Version 10 Database
Terry GOLDBERG
(1) Columbia University Medical Center, United States

**P89** Synchronized Cell Cycle Gene Expression Test for Alzheimer’s Disease
Florin CHIRILA, Daniel ALKON
(1) NeuroDiagnostics LLC, United States

**P90** Soluble TREM2 (Triggering Receptor Expressed on Myeloid cells 2) as a new blood based biomarker in Alzheimer’s disease
Jae-Hong LEE (1), Eun-Hye LEE (2,3), Hyung-Ji KIM (1), Seong-Ho KOH (2,3), So-Hee PARK (4)
(1) Depart of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Korea, Republic of, (2) Department of Neurology, Hanyang University College of Medicine, Korea, Republic of, (3) Department of Translational Medicine, Hanyang University Graduate School of Biomedical Science & Engineering, Korea, Republic of, (4) Seongnam Center of Senior Health, Korea, Republic of

**P91** Neuroinflammation genomic markers in genome-wide association study of Parkinson’s disease
Sun Ju CHUNG (1), Choi NARI (1), Kim JUYEON (2), Kim KIUJU (1), Kim MI JUNG (3), Ryu HO SUNG (4), Jo SUNG YANG (1), Park KYE WON (1)
(1) Asan Medical Center, Korea, Republic of, (2) Metro hospital, United States, (3) Bobath Memorial Hospital, Korea, Republic of, (4) Kyungpook National University Hospital, Korea, Republic of

**P92** Levels of gut microbiota potentially regulated through anti-inflammatory effect identified as associated to response to Blarcamesine (ANAVEX2-73) in Alzheimer’s disease patients in 2-year Interim clinical data using KEM Artificial Intelligence analysis
Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2)
(1) Ariana Pharma, France, (2) Anavex, United States

**P93** Use of translational electroencephalography biomarker in early phase clinical studies for Alzheimer’s disease
Svetlana SEMENOVA (1), Livingly PARK (1), Lev GERTSIK (2), Stanford JHEE (1)
(1) PAREXEL International, United States, (2) California Clinical Trials Medical Group, United States

**P94** Neurophysiological biomarkers parallel glucose hypometabolism in Alzheimer’s disease patients
Shani WANINGER (1), Emily ANGELOPOULOS (1), Chris BERKA (1), Amir MEGHDADI (1), David SALAT (2), Ajay VERMA (3)
(1) Advanced Brain Monitoring, United States, (2) MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, United States, (3) Biogen, United States

**P95** Blood-based Biomarkers for Predicting Neurological Response in Patients with Alzheimer’s disease
Aari MISHRA (1), Gerson HERNANDEZ (1), Claudia LOPEZ (1), Baran AYDOGAN (2), Yonggang SHI (2), Meng LAW (2), Lon SCHNEIDER (3), Roberta BRINTON (1)
(1) Center for Innovation in Brain Science, University of Arizona, United States, (2) Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, United States, (3) Psychiatry, Keck School of Medicine of USC, United States
**POSTERS PRESENTATION**

**THEME 4**
Clinical trials biomarkers

P96  Inflammation markers predicting longitudinal clinical progression in early Alzheimer’s disease
Jagan PILLAI, James BENA, Lynn BEKRIS, Stephen RAO, Bruce LAMB, James LEVERENZ
(1) Cleveland Clinic, United States

P97  Predicting cognitive decline in late middle life using neuronal-derived extracellular vesicles
Erden EREN (1), Jack HUNT (2), Nick VOGT (2), Sterling JOHNSON (2), Barbara BENDLIN (2), Dimitrios KAPOGIANNIS (1)
(1) Laboratory of Clinical Investigations, Intramural Research Program, National Institute on Aging, United States, (2) Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin, United States

P98  Combining Sex, APOE Genotype, and Mitochondrial Genetic Variance As Predictive Responder Identifier to Regenerative Therapeutic Allopregnanolone for Alzheimer’s Disease
Yiwei WANG (1), Christine SOLINSKY (2), Gerson HERNANDEZ (1), Jon SCHNEIDER (2), Roberta BRINTON (2)
(1) University of Arizona, United States, (2) University of Southern California, United States

P99  Soluble TREM2 and Other Immune Factors in Young Adult Down Syndrome
Lynn BEKRIS (1), Katherine KOENIG (2), Grace WEBER (1), Maria KHRESTIAN (1), Yvonne SHAO (1), James LEVERENZ (3)
(1) Cleveland Clinic Lerner Research Institute, United States, (2) Cleveland Clinic Imaging Institute, United States, (3) Cleveland Clinic Neurological Institute, United States

P100 Identifying subsets of patients with mild cognitive impairment and cardiovascular risk factors based on differential expression of angiogenic and inflammatory biomarkers
Zachary WINDER (1), Tiffany L SUDDUTH (2), David FARDO (3), Qiang CHENG (4), Larry B GOLDSTEIN (5), Peter T NELSON (2), Fred A SCHMITT (2), Greg A JICHA (2), Donna M WILCOCK (2)
(1) University of Kentucky Physiology Department, United States, (2) University of Kentucky Sanders-Brown Center on Aging, United States, (3) University of Kentucky Biostatistics Department, United States, (4) University of Kentucky Division of Biomedical Informatics, United States, (5) University of Kentucky Neurology Department, United States

P101 A conformation variant of p53 as a promising blood-biomarker for Alzheimer’s diagnosis at pre-clinical and prodromal stages of the disease
Daniela UBERTI (1, 2), Giulia ABATE (1), Marika VEZZOLI (1), Antonio GUIATA (3), Chris FOWLER (4, 5), Maurizio MEMO (1, 2)
(1) University of Brescia, Italy, (2) Diadem s.r.l., Italy, (3) Golgi Cenci Foundation, Italy, (4) The Florey Institute, Australia, (5) The University of Melbourne, Australia

P102 Neural injury biomarker profiles from the EPOCH Phase 3 trial of verubecestat in patients with mild-to-moderate Alzheimer’s disease
Matthew E. KENNEDY (1), Cyrille SUR (2), James KOST (3), Debra POST (4), Christine FURTEK (5), Julie STROMSWOLD (5), Nicole DUPRE (5), Ryan CLARK (1), Michael F. EGAN (4)

P103 A Machine Learning Approach with Biomarkers for Classification of Mixed Dementia Patients
Gary ROSENBERG (1), Rajikha RAJA (2), Jillian PRESTOPNIK (1), Arvind CAPRIHAN (2)
(1) University of New Mexico, United States, (2) MIND Research Network, United States

P104 Blood Amyloid-β oligomerization associated with brain volume reduction in the form of Alzheimer’s disease
Young Chul YOUN (1), Sangyun KIM (2), Sungmin KANG (3), Seong Soo A. AN (4)
(1) Dept. of Neurology, Chung-Ang Univ. Hospital, Korea, Republic of, (2) Dept. of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Korea, Republic of, (3) Research and Development, PeopleBio Inc., Korea, Republic of, (4) Dept. of Biomanotechnology, Gachon University, Korea, Republic of

P105 Stability of plasma amyloid-β 1-40, amyloid-β 1-42 and total Tau protein over repeated freeze/thaw cycles
W.P. CHEN (1), Huei-Chun LIU (2), Ming-Jang CHIU (3), Chin-Hsien LIN (3), Shieh-Yueh YANG (2, 1)
(1) MagDu LLC, United States, (2) MagDu Co., Ltd., Taiwan, Republic of China, (3) National Taiwan University Hospital, Taiwan, Republic of China

P106 Clinical characteristics and amyloid accumulation in the brain and the blood in amnestic subjective cognitive decline
Yang DONG WON (1), Hong YUN JUNG (1), Ho SEONGHEE (1), Jeong JEE HYANG (2), Park KEE HYUNG (3), Kim SANGYUN (4), Wang MIN JEONG (4), Choi SEONG HYE (5), Han SEUNGHYUN (6)
(1) Department of Neurology, Catholic University of Korea, Korea, Republic of, (2) Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Korea, Republic of, (3) Department of Neurology, Gachon University Gil Hospital, Korea, Republic of, (4) Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Korea, Republic of, (5) Department of Neurology, Inha University School of Medicine, Korea, Republic of, (6) ROWAN Inc., Korea, Republic of
P107 Development of Alzheimer’s disease Biomarker using Aβ*56 Soluble Oligomer in Human Nasal Secretions
I.H. Paik 1*, H.K. Lim 2*
1Department of Psychiatry, Geyo Hospital - Eui Wang (Korea, Republic of), 2Department of Psychiatry, Catholic University of Korea - Seoul (Korea, Republic of)

P108 Qualification of the Fujirebio Lumipulse G β -Amyloid(1-40), β -Amyloid(1-42), Total Tau, and pTau (181) Assays for Measurements in Clinical Study Protocols
Kelley COALIER (1), Rachel HENSON (1), Nathalie LE BASTARD (2), John LAWSON (3), Manu VANDUCK (2), Anne FAGAN (2)
(1) Department of Neurology, Washington University School of Medicine, United States, (2) Fujirebio Europe, Belgium, (3) Fujirebio Diagnostics Inc, United States

P109 Correlation between cognition and plasma noradrenaline level in Alzheimer’s disease: a potential new blood marker of disease evolution
Laure-Elise PILLET (1), Camille TACCOLA (1), Justine COTONI (1), Hervé THIRIEZ (2), Karine ANDRÉ (3), Romain VERPILLOT (1)
(1) Alzohis, France, (2) HEC, France, (3) Statitec, France

P110 Differential effects of the interaction between the education and APOE ε4 allele on amyloid-beta retention and memory performances in cognitively normal older adults and Alzheimer’s disease patients
Dong Woo KANG (1), Hyun Kook LIM (2)
(1) Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea, Republic of, (2) Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea, Republic of

THEME 5
Clinical trials: cognitive and functional endpoints

P111 Development of social cognition enhancement training program for amnestic mild cognitive impairment and early dementia of Alzheimer’s type patients, based on facial emotion recognition pattern analysis
Beomwoo NAM (1), Taehyun KIM (1), Soo Rim NOH (2), Won-Myong BAHK (3), Bo-Hyun YOON (4), Sang-Yeol LEE (5), Kwanghun LEE (6), Moon-Doo KIM (7), Se-Hoon SHIM (8), Dae Bo LEE (9)
(1) Department of Psychiatry, Konkuk University, Korea, Republic of, (2) Department of Psychology, Chungnam National University, Korea, Republic of, (3) Department of Psychiatry, College of Medicine, The Catholic University of Korea, Republic of, (4) Department of Psychiatry, Naju National Hospital, Korea, Republic of, (5) Department of Psychiatry, College of Medicine, Wonkwang University, Korea, Republic of, (6) Department of Psychiatry, School of Medicine, Dongguk University, Korea, Republic of, (7) Department of Psychiatry, School of Medicine, Jeju National Hospital, Korea, Republic of, (8) Department of Psychiatry, College of Medicine, Soonchunhyang University, Korea, Republic of, (9) Department of psychiatry, Mirae Hospital, Korea, Republic of

P112 Using a Global Statistical Test as an Overall Measure of Alzheimer’s disease
Noel ELLISON, Suzanne HENDRIX, Newman KNOWLTON, Sam DICKSON
(1) Pentara Corporation, United States

P113 Leveraging Sex Differences in Cognition and Alzheimer’s to Optimize Clinical Trial Design
Sarah BANKS, Benjamin SHIFFLETT, Erin SUNDERMANN, Steve EDLAND
(1) University of California, San Diego, United States

P114 The OLFACT Test Battery (OTB) predicts Alzheimer’s disease
Lloyd HASTINGS (1), Marie-Elyse LAFAILLE-MAGNAN (2), Steven HOWE (3), Robert WILSON (4)
(1) Osmic Entreprises, United States, (2) McGill University, Canada, (3) SFH Associates LLC, United States, (4) RUSH, United States

P115 Identifying What Matters to People with and at Risk for Alzheimer’s Disease and Their Care Partners: Concept Elicitation and Item Development
George VRADENBURG (1), Brett HAUBER (2), Dana DIBENEDETTI (2), Leigh CALLAHAN (3), Michele POTASHMAN (4), Holly KRASA (5), Ann HARTRY (5), Glen WUNDERLICH (7), Deborah OFFMAN (8), Dan WIEBERG (9), Ian KREMER (10)
(1) UsAgainstAlzheimer’s, United States, (2) RTI Health Solutions, United States, (3) University of North Carolina, United States, (4) Biogen, Inc., United States, (5) OTSUKA Pharmaceutical Development & Commercialization, United States, (6) Lundbeck LLC, United States, (7) Boehringer Ingelheim (Canada) Ltd., Canada, (8) Taike Pharmaceuticals, United States, (9) Home Instead, Inc., United States, (10) LEAD Coalition (Leaders Engaged on Alzheimer’s Disease), United States

P116 Analysis of the Rates and Types of Errors on Paper Administration of the Neuropsychiatric Inventory
Sarah KARAS, Todd FEASTER, Bomi HONG
(1) Signant Health, United States

P117 Analysis of the Rates and Types of Errors on the Cohen-Mansfield Agitation Inventory in Agitation in Dementia Clinical Trials
H Todd FEASTER, Bomi HONG, Sarah KARAS
(1) Signant Health, United States
POSTERS PRESENTATION

THEME 5
Clinical trials: cognitive and functional endpoints

P118  Functional activity of the muscarinic positive allosteric modulator VU319 during a Phase I Single Ascending Dose study
Alexander C. CONLEY (1), Alexandra P. KEY (1, 2), Jennifer U. BLACKFORD (1), Jerri M. ROOK (3), P. Jeffrey CONN (3), Craig W. LINDSLEY (3), Carrie K. JONES (3), Paul A. NEWHOUSE (1, 4)
(1) Center for Cognitive Medicine, Vanderbilt University Medical Center, United States, (2) Vanderbilt Kennedy Center, Vanderbilt University Medical Center, United States, (3) Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, United States, (4) Genetic Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System, United States

P119  LIFE-DSR Study: A 3-year longitudinal observational cohort study
William MOBLEY (1), James HENDRIX (2), Anna BURKE (3), George CAPONE (4), Brian CHICOINE (5), Alberto COSTA (6), Anna ESBENSEN (7), Sarah HART (8), Elizabeth HEAD (9), Priya KISHNANI (8), Florence LAI (10), Ira LOIT (9), Cesar OCHOA-LUBINOFF (11), Herminia Diana ROSAS (10), Tracie ROSSER (12), Stephanie SANTORO (10), Frederick SCHMITT (13), Stephanie SHERMAN (12), Brian SKOTKO (10), Amy TALBOY (12)
(1) UCSF, United States, (2) LuminindISC, United States, (3) Barrow Neurological Institute, United States, (4) Kennedy Krieger Institute, United States, (5) Advocate Health, United States, (6) Case Western Reserve University, United States, (7) Cincinnati Children’s Hospital, United States, (8) Duke University, United States, (9) UCI, United States, (10) Massachusetts General Hospital, United States, (11) Rush University Medical Center, United States, (12) Emory University, United States, (13) University of Kentucky, United States

P120  An observational study in real world daily clinical practice to evaluate the effect of the medical food Souvenaid on instrumental activities of daily living in people with mild Alzheimer’s Disease
Janneke DE WILDE (1), Gijsbertus ZIERE (2, 3), Vincent VANNESTE (4), Kees KALISVAART (5), Megan HERBERT (1), Leo BOELAARTS (6), Sietske SIKKES (7)
(1) Danone Nutricia Research, Netherlands, (2) Department of Geriatrics, Havenpoolliniek, Maasstad Ziekenhuis, Netherlands, (3) Alzheimer Center Zuidwest Nederland, Erasmus Medisch Centrum, Netherlands, (4) Franciscus Ziekenhuis, Netherlands, (5) Department of Geriatrics, Spaarne Gasthuis, Netherlands, (6) Department of Geriatric Medicine, Noordwest Hospital Group, Netherlands, (7) Alzheimer Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Netherlands

P121  Comparing the Results of a Consensus Expert Diagnosis with Outcomes Based on the Syndrom-Kurztest (SKT), a Short Cognitive Performance Test: Indications for Convergent Validity
Mark STEMMLER (1), Hartmut LEHFEID (2), Katya NUMBERS (3), Perminder SACHDEV (3), Henry BRODATY (3)
(1) University of Erlangen-Nuremberg, Germany, (2) University of Erlangen-Nuremberg/Department of Psychiatry and Psychotherapy, Paracelsus Medical University, Germany, (3) Centre for Healthy Brain Ageing (CHEBA), University of New South Wales, School of Psychiatry, Australia

P122  Comparisons between ADAS-Cog 11 and CDR System measures in the assessment of cognitive dysfunction in mild to moderate Alzheimer’s disease
Pascal GOETGHEBEUR (1), Daniela DIGREGORIO (2), Martina MICALETTO (1), Marcella ROY (3), Juha ROURU (4), Keith WESNES (1)
(1) Signant Health, United Kingdom, (2) Signant Health, United States, (3) Signant Health, Czech Republic, (4) Signant Health, Finland

P123  Precision Functional Assessment for Alzheimer’s Disease (PFA-AD): A pilot study framework
Gerson HERNANDEZ (1), Claudia LOPEZ (1), Iran GISLER (2), Dana WERSHNER (2), Vicki SEYFERT-MARGOLIS (2), Roberta BRINTON (1)
(1) OBS, University of Arizona, United States, (2) Myownmed, United States

P124  Effects of Dietary Flaxseed on Memory and Cognition
Benedict ALBENS, Claudia CORDES-PEREZ, Aida ADJMOUGHADDAM
(1) St Boniface Hospital Research, Canada

P125  Neuropsychological correlates of Alzheimer disease biomarkers
Matthias RIEPE, Claudia LANZA, Karolina SEJUNAITE
(1) Ulm University, Germany

P126  Effects of Supplement Containing Aserine on Cognitive Functions in People with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial
N. Masuoka (1), S. Shiotsuki (2), N. Yanai (2), K. Sato (2), T. Hisatsune (1)*
(1) The University of Tokyo - Tokyo (Japan), (2) Tokai Bussan Co., Ltd - Tokyo (Japan)

P127  An observational study in real world daily clinical practice to evaluate the effect of a medical food on activities of daily living in people with early Alzheimer’s Disease
Gijsbertus ZIERE (1), Vincent VANNESTE (2), Kees KALISVAART (3), Janneke DE WILDE (4), Megan HERBERT (4), Leo BOELAARTS (5), Sietske SIKKES (6)
(1) Department of Geriatrics, Havenpoolliniek, Maasstad Ziekenhuis, Netherlands, (2) Franciscus Ziekenhuis, Netherlands, (3) Danone Nutricia Research, Netherlands, (4) Department of Geriatric Medicine, Noordwest Hospital Group, Netherlands, (5) Department of Geriatric Medicine, NWO West Hospital Group, Netherlands, (6) Alzheimer Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Netherlands

P128  Sex Differences in Predictors of Cognitive and Functional Outcomes in Patients with Alzheimer’s Disease
Carina WATIMÓ, Asa K. WALLIN, Elisabet LONDO
(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden

P129  The ADAS-Cog-Exec: A Novel Cognitive Composite Outcome to Assess Therapeutic Effects of Exercise in the EXERT Trial for Adults with MCI
Diane JACOBS (1), Ronald THOMAS (1), David SALMON (1), Sheila JIN (1), Howard FELDMAN (1), Carl COITAN (2), Laura BAKER (3)
(1) Alzheimer’s Disease Cooperative Study, UC San Diego, United States, (2) Institute for Memory Impairments and Neurological Disorders, UC Irvine, United States, (3) Wake Forest School of Medicine, United States
P130  A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia
Jay Kwon (1), Kyung-soo Lee (2), Nack-Cheon Choi (2)
(1) Changwon Fatima Hospital, Korea, Republic of, (2) Samsung Medical Center, Korea, Republic of

P131  HAPPCAP-AD (Human-APPLICATION Combined Approach for Prevention of Alzheimer's Disease)
Ithamar Ganmore (1,*), Ramit Ravon-Springer (1), Adar Matatov (1), Ariela Ben-Moshe (1), Michal Beeri Schnaider (1, 2,*)
(1) Joseph Sagol Neuroscience Center at Sheba Medical center - Tel-Hashomer, Israel, (2) The Icahn School of Medicine at Mount Sinai - New-York, United States

THEME 6
Cognitive assessment and clinical trials

P132  Estimating subject-specific variance in unsupervised, high-frequency, mobile app based cognitive testing: feasibility of using mobile apps for monitoring cognitive safety
Emrah Düzel (1), David Berron (2), Michael T. Heneka (1), Anja Schneider (1), Stefan J. Teipel (1), Michael Wagner (1), Frank Jessen (1)
(1) German Center for Neurodegenerative Diseases, Germany, (2) Clinical Memory Research Unit, Lund University, Sweden

P133  Inter-Site Variability and Standardization of AD and MCI Diagnoses
Nicolas Pannetier, Thomas Liebmann, Elham Khosravi, Pavan Krishnamurthy, Padideh Kamali-Zare, Kaveh Vehdani
(1) Darmiyan, Inc, United States

P134  Frequency of and Factors Associated with Environmental Distraction During Unsupervised Digital Cognitive Assessment
Nicholas Bott (1, 2), John Anderson (2), Doug Newton (2), Aidan Hall (2), Jordan Glenn (2), Erica Madero (2), Nami Fuseya (2)
(1) Stanford University School of Medicine, United States, (2) Neurotrack Technologies, Inc., United States

P135  Evaluating a method for automatic and objective scoring of verbal responses for the Montreal Cognitive Assessment (MoCA)
Liam Kaufman, Aparna Balagopalan, Jekaterina Novikova, Fariya Mostafa
(1) Winterlight Labs, Canada

P136  Staging Early Alzheimer's Disease Using the Alzheimer's Disease Composite Score (ADCOMS)
Amir Abbas Tahami Monfared (1), Katherine Stull (2), Quanwu Zhang (1)
(1) Eisai Inc., United States, (2) RTI Health Solutions, United States

P137  Altoida Neuro Motor Index (NMI): Digital Biomarkers for Rapid and Reliable Cognitive and Functional Assessment in Alzheimer's Disease Clinical Trials
Ioannis Tarnanas (1), Irene Meier (1), Maximilian Bügler (1), Robbert Harms (1), Claudio Babiloni (2), Mircea Balasa (3), Giovanni Frisoni (4), Michaela Rampini (4), Robert Whelan (5), Vlamos Pandiotis (6)
(1) Altoida, United States, (2) Sapienza University of Rome, Italy, (3) Hospital Clinic de Barcelona, Spain, (4) IRCCS S Giovanni di Dio Fatebenefratelli, Italy, (5) Trinity Inst. of Neurosciences, Ireland, (6) Ionian University, Greece

P138  Early development of a unified, speech and language composite to assess clinical severity of Frontotemporal Lobar Degeneration (FTLD)
William Simpson (1), Aparna Balagopalan (2), Liam Kaufman (2), Jekaterina Novikova (2), Omer Siddiqui (3), Robert Paul (3), Mike Ward (3)
(1) McMaster University, Canada, (2) Winterlight Labs, Canada, (3) Alector, United States

P139  The Comparison of Cognitive Inclusion Scores Between Subjects Screened in the Morning versus Screened in the Afternoon
Katherine Kruczek, Pamela Voccia
(1) Bioclinica Research, United States

P140  Underlying Potential Mechanism of Anti-Alzheimer’s Disease Using Mausin Derivative Iosorrientin 2-D-a-l-rhamnoside using in Vitro Assay System
Grace Lena, Hong-Duck Kim
(1) New York Medical College, United States

P141  Evaluation of Proper Names in Semantic Memory Tasks with Subjects Presenting for Alzheimer’s Dementia Research Trials
Katherine Kruczek, Pamela Voccia, Michelle Cohen
(1) Bioclinica Research, United States

P142  Gender bias in clinical trial recruitment in AD: an analysis by Fundacio ACE
Mercè Boada (1, 2), Carla Abdelnour (1, 2), Antonella Santuccione (3, 4), Maria Teresa Ferretti (3, 5), Peggy Maguire (6), Isabel Hernández (1, 2), Asunció Lafuente (1), Juan Pablo Tartari (1), Mar Buendía (1), Ana Pancho (1), Lluís Tarraga (1, 2), Alba Espaniel (1), Miren Jone Gurutxaga (1), Agustín Ruiz (1, 2), Sergio Valero (1, 2)
(1) Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya-Barcelona, Spain, (2) Networking Research Center on Neurodegenerative Disease (CIBERNED), Instituto de Salud Carlos III, Spain, (3) Women’s Brain Project, Gunthershausen, Switzerland, (4) 6. Global Medical and Scientific Affairs, Roche Diagnostics International Ltd., Rotkreuz, Switzerland, (5) 4. Institute for Regenerative Medicine-IREM, University of Zurich, Schlieren, Zurich, Switzerland, (6) 7. European Institute of Womens Health, Dublin, Ireland

P143  A Look at Practice Effect for Word List Recall in Subjects Presenting for Clinical Trials in Alzheimer’s Disease
Katherine Kruczek, Pamela Voccia, Michelle Cohen
(1) Bioclinica Research, United States

CTAD San Diego 2019
THEME 6
Cognitive assessment and clinical trials

P144  Using Hierarchical Bayesian Cognitive Processing and Latent-Mixture Models to Predict Impending Cognitive Decline with Common Memory Tests
Michael LEE (1), Jason BOCK (2), William SHANKLE (2, 1, 3), Junko HARA (2, 3), Dennis FORTIER (2), Tushar MANGROLA (2), Ronald PETERSEN (4)
(1) Dept. of Cognitive Sciences, University of California at Irvine, United States, (2) Medical Care Corporation, United States, (3) Pickup Family Neurosciences Institute, Hoag Memorial Hospital, United States, (4) Mayo Clinic, United States

P145  Changes in semantic memory due to cognitive impairment in Alzheimer’s patients
Holly WESTFALL (1), Jason BOCK (2), Tushar MANGROLA (2), Michael LEE (1)
(1) University of California, Irvine, United States, (2) Medical Care Corporation, United States

P146  Progress & Challenges in the Development of Electronic Instruments to Predict and Monitor Cognitive Decline
Taylor HOWELL (1), Rachel NOSHENY (1), Scott MACKIN (1), Diana TRURAN (1), Erik ROBERSON (2), Richard KENNEDY (2), Martin ROY (2), Daniel MARSON (2), Adam GERSTENECKER (2), John MORRIS (3), Virginia BUCKLES (3), Krista MOULDER (3), Chengjie XIONG (3), Yan LI (3), Andrew ASCHENBRENNER (3), Dan MUNGAS (4), Michael WEINER (1)
(1) University of California, San Francisco, United States, (2) University of Alabama - Birmingham - Birmingham (United States), United States, (3) Washington University at St. Louis, United States, (4) University of California, Davis, United States

P147  Elucidating the risk factors for disease progression in dementia patients with amnoid negative amnestic mild cognitive impairment
Hyung Ji KIM, Eunjoon RHEE, Sungeun CHUNG, Jae-Hong LEE
(1) Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Korea, Republic of

P148  Comparing the Standard and Electronic Versions of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale: A Validation Study
Diana MICHALCZUK (1), Todd SOLOMON (2, 3), Jordan BARBONE (2), Todd FEASTER (2), David MILLER (2), Guy DEBROS (1), Cynthia MURPHY (1)
(1) The Memory Clinic, United States, (2) Signant Health, United States, (3) Boston University School of Medicine, United States

P149  Asian and Non-Asian Countries Screen Subjects with Similar MMSE Scores to the Elenbecestat MissionAD Global Phase 3 Studies in Early Alzheimer’s disease
Jennifer MURPHY (1), Thomas DOHERTY (2), Michelle GEE (3), Satoshi ITO (4), Kanekiyo MICHI (4), Bruce ALBABA (5)
(1) Syneos Health, United States, (2) Syneos Health, United Kingdom, (3) Eisai, United Kingdom, (4) Eisai, Japan, (5) Eisai, United States

P150  Comparing a speech-based digital biomarker to the Montreal Cognitive Assessment (MoCA) for tracking cognition over a 6 month period in a naturalistic cohort of older adults
William SIMPSON (1, 2), Aparna BALAGOPALAN (2), Liam KAUFMAN (2), Maria YANCHEVA (2)
(1) McMaster University, Canada, (2) Winterlight Labs, Canada

P151  Discrimination of Alzheimer’s dementia from other dementia with three different dementia screening questionnaires
Seonghee HO (1), Dong Won YANG (1), Ahro KIM (1), Dong Woo LEE (2), Hyun Jeong HAN (3), Jee Hyang JEONG (4), Jun Hong LEE (5), Jun-Young LEE (6), Kee Hyung PARK (7), Kyung Won PARK (8), Sangyun KIM (9), Seong Hye CHOI (10), Young Chul YOUN (11)
(1) The Catholic University of Korea, Seoul St. Mary’s Hospital, Korea, Republic of, (2) Inje University Sanggye Paik Hospital, Korea, Republic of, (3) Myongji Hospital, Korea, Republic of, (4) Ehwa Womans University Mokdong Hospital, Ehwa Womans University School of Medicine, Korea, Republic of, (5) National Health Insurance Corporation Ilsan Hospital, Korea, Republic of, (6) Seoul National University College of Medicine & SMG-SNU Boramae Medical Center, Korea, Republic of, (7) Gachon University Gil Hospital, Korea, Republic of, (8) Cognitive Disorders and Dementia Center, Dong-A University College of Medicine, Korea, Republic of, (9) Seoul National University College of Medicine, Seoul National University Bundang Hospital, Korea, Republic of, (10) Inha University School of Medicine, Korea, Republic of, (11) Chung-Ang University Hospital, Korea, Republic of

P152  Novel Digitalized Markers for Screening, Cognitive Assessments and Disease Trajectory Tracking in Clinical trials
Alexandra KÖNIG (1), Nicklas LINZ (2), Johannes TRÖGER (2), Rachid GUERCBOUCHE (3), Zeghari RADIA (4), Ramakers INEZ (5), Aalten PAULINE (5), Robert PHILIPPE (4)
(1) INRIA, Cobek (Cognition, Behaviour, Technology) Lab, University Côte d’azur, France, (2) German Research Center for Artificial Intelligence (DFKI), Germany, (3) INRIA, France, (4) Cobek (Cognition, Behaviour, Technology) Lab, University Côte d’azur, France, (5) Alzheimer Limburg Center, Maastricht University, Netherlands

P153  Tracking functional decline in Mild Cognitive Impairment
Kevin DUFF, Sariah PORTER, Kayla SUHRIE, Ava DIXON, Dustin HAMMERS
(1) University of Utah, United States

P154  Cognitive functioning on the RBANS and APOE status
Kevin DUFF, Kayla SUHRIE, Sariah PORTER, Ava DIXON, Dustin HAMMERS, John HOFFMAN
(1) University of Utah, United States

P155  The predictive validity of the SKT short cognitive performance test for the detection of early cognitive decline
Mark STEMMLER (1), Johannes HESSLER (2), Horst BICKE (2), Hartmut LEHFEID (3)
(1) University of Erlangen-Nuremberg, Germany, (2) Technical University of Munich (TUM), Germany, (3) Paracelsus Medical University, Germany

P156  The Frequency Of Orthostatic Hypotension In Older Patients With Alzheimer Disease Is Similar In Those With Lewy Body Dementia
Ahmet Turan ISIK (1), Suleyman Emre KOÇYIGIT (1), Lee SMITH (2), Ali Ekrem AYDIN (1), Fınar SOYSAL (1)
(1) Unit for Aging Brain and Dementia, Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey, Turkey, (2) The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom
P157 Neuropsychological, Psychiatric, and Functional Correlates of Clinical Trial Enrollment
Dustin HAMMERS, Norman FOSTER, John HOFFMAN, Thomas GREENE, Kevin DUFF
(1) University of Utah, United States

THEME 7 Behavior disorders and clinical trials

P158 Relationship between awareness disturbance and behavioural disorders in Alzheimer disease
Stefania ROSSI (1), Gianna Carla RICCITELLI (1), Nadia PARIETTI (1), Pietro TIRABOSCHI (2), Carlo DEFANTI (3), Leonardo SACCO (1)
(1) Neurocenter of Southern Switzerland, Neuropsychological Service, Ospedale Regionale di Lugano, Switzerland, (2) Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Neurology 5 and Neuropathology, Italy, (3) Centro Alzheimer, Fondazione Europea di Ricerca Biomedica, Italy

P159 Searching for the best outcome for clinical trials for Agitation symptoms in AD: CMAI vs NPI-C. Results from the A3C study
Maria SOTO MARTIN (1), Adelaide DE MAULEON (1), Zahinoor ISMAIL (2), Jeannie Marie LEOUTSAKOS (3), David MILLER (4), Paul ROSENBERG (3), Sandrine ANDRIEU (1), Bruno VELLAS (1), Constantante LYKETSOS (3)
(1) Alzheimer Disease Clinical and Research Center, Gerontopole, Toulouse University Hospital, France, (2) Hotchkiss Brain Institute and O’Brien Institute for Public Health, University of Calgary, Canada, (3) Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview, Johns Hopkins University, United States, (4) Sigannt Healt, United States

P160 Measuring apathy in Alzheimer’s disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): a comparison of instruments
Krista LANCTOT (1), Roberta SCHERER (2), Abby LI (3), Mahwesh SALEEM (3), Danielle VIEIRA (3), Paul ROSENBERG (2), Nathan HERRMANN (4), Alan LERNER (5), Prasad PADALA (6), Olga BRAWMAN-MINZTER (7), Christopher VAN DYCK (8), Anton PORSTEINSSON (9), Suzanne CRAFT (10), Allan LEVEY (11), William BURKE (12), Jacobo MINTZER (13)
(1) Sunnybrook Research Institute, Canada, (2) Johns Hopkins University, United States, (3) Sunnybrook Research Institute, Canada, (4) Sunnybrook Health Sciences Centre, Canada, (5) Case Western Reserve University, United States, (6) University of Arkansas for Medical Sciences, United States, (7) Medical University of South Carolina, United States, (8) Yale University, United States, (9) University of Rochester, United States, (10) Wake Forest School of Medicine, United States, (11) Emory University, United States, (12) Banner Alzheimer’s Institute, United States, (13) Roper St. Francis Healthcare, United States

P161 Behavioral symptoms in Alzheimer’s disease: Results of cholinergic loading therapies with a cholinesterase inhibitor and the cholinergic precursor choline alphoscerate
Enea TRAINI (1), Anna CAROTENUTO (2, 3), Angiola FASANARO (3), Valentino MANZO (3), Francesco AMENTA (1)
(1) Clinical Research, Telemedicine and Telepharmacy Centre, University of Camerino, Italy, (2) Clinical Research, Telemedicine and Telepharmacy Centre, University of Camerino, Italy, (3) Neurology Unit, National Hospital, “A. Cardarelli”, Italy

P162 Empirically-defined Neuropsychiatric Syndromes of Dementia
Lon S. SCHNEIDER (1), Anton Y. BESPALOV (2, 3), Hans J. MOEBIUS (3), Timofey L. GALANKIN (2)
(1) Keck School of Medicine of USC, United States, (2) Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, Russian Federation, (3) Exciva UG, Germany

P163 REIMAGINE-AD: Safety and efficacy of vafidemstat for the treatment of Alzheimer’s disease related aggression
Michael ROPACKI (1), Merce BOADA (2), Sonia GUTIERREZ (1), Roger BULLOCK (1), Carlos BUESA (1)
(1) Oryxon Genomics SA, Spain, (2) Fundació ACE. Barcelona Alzheimer Treatment and Research Center, UIC-Barcelona, Spain

P164 Sex Differences in Subjective Age-Associated Changes in Sleep: A Prospective Elderly Cohort Study
Seung Wan SUH
(1) Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Korea, Republic of

THEME 8 Health economics and clinical trials

P165 The Effects of physical, intellectual, social and healthy diet activities to the instrumental activities of daily living and caregiver burden of the patients with minor or major neurocognitive disorders
Bon D. KU (1, 2), Youn Sun PARK (1), Ji Y. KIM (1), Hyun Geun PARK (2), Yang Jin KIM (2), Jung Han SEO (2)
(1) Department of Neurology, International St. Mary’s Hospital, Korea, Republic of, (2) Catholic Kwandong University College of Medicine, Korea, Republic of

THEME 9 Epidemiology and clinical trials

P166 Tumor Necrosis Factor Blocking Agents Reduce Risk for Alzheimer’s Disease in Patients with Co-morbid Rheumatoid Arthritis and Psoriasis
Mark GURNEY (1), Mengshi ZHOU (2), Rong XU (2)
(1) Itea Therapeutics, United States, (2) Case Western Reserve University, United States
THEME 9
Epidemiology and clinical trials

P167 Antiviral therapy reduces the risk of dementia in patients with herpes zoster: a propensity score-matched analysis
Woon YOON (1), Seongman BAE (1), Sung-Cheol YUN (2), Min-Chul KIM (3), Sang-Oh LEE (1), Sang-Ho CHOI (1), Yang Soo KIM (1), Jun Hee WOO (1), Seong Yoon KIM (1), Sung-Han KIM (1)
(1)Asan Medical Center, Korea, Republic of, (2)Asan Medical Center - Seoul (Korea, Republic of), Korea, Republic of, (3)Chung-Ang University Hospital, Korea, Republic of

P168 Effectiveness of the open screening programs in recruiting subjects to prodromal and mild Alzheimer’s disease clinical trials
Daniel WOJCIK (1, 2), Katarzyna SZCZECIOWIAK (1), Marzena ZBOCH (1)
(1)Wroclaw Alzheimer’s Center, Poland, (2)Division of Quality Services, Procedures and Medical Standards, Medical University in Lodz, Lodz, Poland, Poland

P169 Transition of Prescription Pattern of Antidepressants in Parkinson’s disease and Dementia patients; 2012-2015, South Korea
Yoonah PARK
(1)Kashin university Gospel hospital, Korea, Republic of

P170 Risk of stroke in patients with Alzheimer’s disease
Jun Hong LEE
(1)National Health Insurance Service Ilsan Hospital, Korea, Republic of

P171 Potentially inappropriate medication of psychotropic drugs among elderly people with dementia
Ricardo SALINAS-MARTINEZ, Rocio MORALES-DELGADO, Daniel Gerardo GAMEZ-TREVIÑO, Edgar JIMENEZ-ALARCON, Alfonso DE LA GARZA-VILLARREAL, David Alberto AGUILAR-MACIAS
(1)Geriatrics Unit Hospital Universitario “Dr Jose Eleuterio Gonzalez” UANL, Mexico

THEME 10
Animal models and clinical trials

P172 Neuronal Pentraxin 2: Biomarker and Mechanism Across the Aging/Alzheimer’s Spectrum
Michela GALLAGHER, Audrey BRANCH, Rebecca HABERMAN
(1)Johns Hopkins University, United States

P173 Isogenic iPSC model of CHRFAM7A effect on α7 nicotinic acetylcholine receptor for preclinical high throughput screen
Kinga SZIGETI (1), Iwona INNATOWICZ (1), Barbara BIRKAYA (1), Dinesh INDURTHI (1), Radhakrishnan GNANASAMBANDAM (1), Aya OUF (1), Norbert SULE (2), Lee CHAVES (1), Anthony AUERBACH (1)
(1)SUNY at Buffalo, United States, (2)Roswell Park Comprehensive Cancer Center, United States

P174 Pharmacological profiles of anti-amyloid β aggregate-specific antibody KHK6640 both in vitro and in vivo including a novel clinically relevant rodent model of Alzheimer’s disease
Shinichi UCHIDA, Koji YAMADA, Takako HORITA, Nobuyuki SUZUKI, Yui SUZUKI, Kenichiro SUGIYAMA
(1)Kyowa Kirin Co., Ltd., Japan

P175 The BUENA Study: A Phase 2A Clinical Trial To Test Safety and Efficacy of Montelukast Versafilm™ in Alzheimer’s Patients
Ludwig AIGNER (1), Johanna MICHAEL (1), Justin CONWAY (2), Frank PIETRANTONIO (2), Horst ZERBE (2), Nadine PAIEMENT (2)
(1)Paracelsus Medical University, Austria, (2)Intelgenx, Canada

P176 Mechanisms of interference by Alzheimer’s Disease symptomatic treatments with tau aggregation inhibitor activity in a tau-transgenic mouse model
Gernot RIEDEL (1), Jochen KLEIN (2), Grzegorz NIEWIADOMSKA (3), Charles R HARRINGTON (1, 4), Claude M WISCHIK (1, 4)
(1)University of Aberdeen, United Kingdom, (2)Goethe University Frankfurt, Germany, (3)Nencki Institute, Poland, (4)TauRx Therapeutics Ltd, United Kingdom

P177 Low dose brain irradiation reduces amyloid β and tau in 3xTg mice
James FONTAINES (1), Thomas G WILSON (1), Aila HANNA (1), Daniel B MICHAEL (1), Prakash CHINNAIYAN (1), Michael M MADDEN (1), Alvaro A MARTINEZ (2), George D WILSON (3)
(1)Beaumont Health Systems, United States, (2)Michigan Healthcare partners, United States, (3)Beaumont Heal Sysytems, United States

THEME 11
New therapies and clinical trials

P178 A 12-week physical exercise intervention to prevent cognitive decline and disability in Korean at-risk elderly people: a pilot study
Sun Min LEE (1), Hong-Sun SONG (2), Muncheong CHOI (3), Hye Mi KWON (1), Hyesu JEON (4), Da Eun SEO (4), Seonghye CHOI (5), So Young MOON (1)
(1)Department of Neurology, Ajou University School of Medicine, Korea, Republic of, (2)Department of Sports Sciences, Ajou University Institute of Sport Science, Korea, Republic of, (3)College of Physical Education and Sports Science, Kookmin University, Korea, Republic of, (4)Department of Psychology, Ajou University, Korea, Republic of, (5)Department of Neurology, Inha University College of Medicine, Korea, Republic of
P179  BAN2401 In Early Alzheimer’s Disease: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety And Efficacy (CLARITY AD)
Shau Yu LYNCH (1), Michael IIRIZARRY (1), Shobha DHADDA (1), Yong ZHANG (1), Jinping WANG (1), Tanya BOGOSLOVSKY (1), Larisa REYDERMAN (1), Juno KAPLOW (1), Heather BRADLEY (1), Martin RABE (1), Keiichiro TOTSUKA (2), Lynn KRAMER (1), Harald HAMPEL (1), Chad SWANSON (1)
(1) Eisai Inc, United States, (2) Eisai Co, Ltd, Japan

P180  Masupirdine (SUVN-502), in combination with donepezil and memantine in moderate Alzheimer’s Disease - Effect of AD duration since diagnosis on efficacy endpoints
Ramakrishna NIROGI (1), John JENI (1), Vinod GOYAL (1), Pradeep JAYARAJAN (1), Venkat JASTI (1), Jeffrey CUMMINGS (2)
(1) Suven Life Sciences, Serene Chambers, Banjara Hills, Hyderabad, India, (2) Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States

P181  AD diagnosis duration in combination with memantine exposures on Masupirdine (SUVN-502) efficacy - Masupirdine in combination with donepezil and memantine in moderate Alzheimer’s disease patients
Ramakrishna NIROGI, Pradeep JAYARAJAN, Jyothsna RAVULA, Vinod GOYAL, Anil SHINDE, Satish JETTA, Abraham RENNY, Gopi BHYRAPUNENI, Venkat JASTI
(1) Suven Life Sciences, Serene Chambers, Banjara Hills, Hyderabad, India

P182  Exploratory subgroup analyses based on patient’s age and its effect on cognitive endpoints - Masupirdine (SUVN-502), triple therapy with donepezil and memantine in moderate Alzheimer’s disease patients
Ramakrishna NIROGI, Anil SHINDE, Vijay BENADE, Gopi BHYRAPUNENI, Satish JETTA, Pradeep JAYARAJAN, Vinod GOYAL, Santoshkumar PANDEY, Venkat JASTI
(1) Suven Life Sciences, Serene Chambers, Banjara Hills, Hyderabad, India

P183  Baseline ADAS-Cog 11 scores and its effect on cognitive endpoints - Masupirdine (SUVN-502), triple therapy with donepezil and memantine in patients with moderate Alzheimer’s Disease
Ramakrishna NIROGI, Satish JETTA, Gopi BHYRAPUNENI, Raghava PALACARLA, Anil SHINDE, Pradeep JAYARAJAN, Vinod GOYAL, Subramanian RAMKUMAR, Venkat JASTI
(1) Suven Life Sciences, Serene Chambers, Banjara Hills, Hyderabad, India

P184  Repurposing igmesine for the treatment of neurodegenerative diseases
Vanessa VILLARD (1, 2), Johann MEUNIER (1), Alexander PREGIZER (2), Dorothee BUTTIGIEG (3), Francois ROMAN (1, 2)
(1)Amylegen SAS, France, (2)SigmaThera SAS, France, (3)NeuronExperts SAS, France

P185  Evaluation of digital application MUSIC CARE© associated with personal hygiene care based on the good practices of nursing aides in long-term care facilities (EHPAD): a controlled, randomised study
Jacques TOUCHON (1, 2), Auguste LOKO (3), Stephane GUETIN (4)
(1) University Montpellier 1, France, (2) INSERM U1061, France, (3) University UPMC Paris, France, (4) University Paris 5, France

P186  In vivo efficacy of a small molecule inhibitor targeting tau self-association in both AD and tauopathy models
James MOE (1), Patricia LOPEZ (1), Heidy JIMENEZ (2), Leslie ADRIEN (3), Peter DAVIES (2), Eliot DAVIDOWITZ (1)
(1) Oligomerix.com, United States, (2) The Feinstein Institutes for Medical Research, United States

P187  The Neuroprotective Effect Of A New Photobiomodulation Technique On Aβ25-35 Peptide-Induced Toxicity Dramatically Impact Gut Microbiota Dysbiosis
Jacques TOUCHON (1, 2), Guillaume BLIVET (3), Laura AUBOYER (3), Johann MEUNIER (4), Laura CECILIN (4), Francois J. ROMAN (4), Rémy BURCELIN (5)
(1) INSERM U1061, France, (2) Neurology Department, University of Montpellier, France, (3) REGENLIFE SAS, France, (4) AMYLGEN SAS, France, (5) Vaiomer SAS, France

P188  A Precision Medicine Multimodal Lifestyle Intervention for Treating Cognitive Impairment: Conceptual Framework of the PREVENTION Trial
Sarah MCEWEN (1, 2), David MERRILL (1, 2), Jennifer BRAMEN (1, 2), Verna PORTER (1, 2), Stella PANOS (1), Scott KAISER (1), Laura HEATH (3), Cory FUNK (3), Molly RAPOZO (1), Nathan PRICE (3), Mary Kay ROSS (3), Lee HOOD (3), Jared ROACH (3)
(1) Pacific Neuroscience Institute, 2125 Arizona Avenue, United States, (2) John Wayne Cancer Institute, Department of Translational Neurosciences & Neurotherapeutics, 2200 Santa Monica Blvd, United States, (3) Institute for Systems Biology, 401 Terry Avenue North, United States

Nazneen DEWJI (1), Archie THURSTON (2), Darryl RIDEOUT (3)
(1) Cenna Biosciences Inc, United States, (2) Admesolutions Inc, United States, (3) DxoRx Chemistry, United States

P190  Synaptic intervention in Alzheimer’s disease: soluble Aβ oligomer directed ACU193 monoclonal antibody therapeutic for treatment of early Alzheimer’s disease
Ericka CLINE (1), Kirsten VIOLA (1), William KLEIN (1), Xueying WANG (2), Brian BACSKAI (2), Gerhard RAMMES (3), JC DODART (4), Jorge PALOP (5), Eric SIEMERS (6), Jasna JERECIC (6), Grant KRAFFT (6)
(1) Northwestern University, United States, (2) Harvard University, United States, (3) Technische Universitat Munchen, Germany, (4) United Neuroscience, Ireland, (5) Gladstone Institute, United States, (6) Acumen Pharmaceuticals, United States
P191 Lysergic Acid Diethylamide as a Prospective Multi-Target Disease Modifying Therapeutic in AD: Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Neiloufar FAMILY, Emeline MAILLET, Charles NICHOLS, Shlomi RAZ
(1) Eleusis, United Kingdom

P192 Epigenetic Modulator Apabetalone Inhibits Monocyte Adhesion To Brain Endothelial Cells By Downregulating Key Neuroinflammation Markers In Vitro And In Vivo
Ewelina KULIKOWSKI (1), Sylwia WASIAK (1), Emily DAZE (1), Laura M. TSUJIKAWA (1), Shovon DAS (1), Li FU (1), Dean GILHAM (1), Brooke D. RAKAI (1), Stephanie C. STOTZ (1), Christopher D. SARSONS (1), Deborah STUDER (2), Kristina D. RINKER (2), Ravi JAHAGIR DAR (1), Norman C. W. WONG (1), Michael SWEENEY (3), Jan O. JOHANSSON (3)
(1) Resverlogix Corp, Canada, (2) University of Calgary, Canada, (3) Resverlogix Corp, United States

P193 Acupuncture with Golden Thread in Chronic Headache
Yoonah PARK
(1) Koshin university Gospel hospital, Korea, Republic of

P194 A Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD, an Anti-Alzheimer's Disease Epichaperome Inhibitor
Michael H SILVERMAN (1), Jeffrey CUMMINGS (2), Susan DUGGAN (1), Barbars WALLNER (1)
(1) Samus Therapeutics, United States, (2) Cleveland Clinic Lou Ruvo Center for Brain Health, United States

P195 Clinical phase I data of the first orally available anti-Ab-prionic PRI-002 that reverses behavior and cognitive deficits, and decelerates neurodegeneration in transgenic AD mouse models
Dieter WILLBOLD (1, 2, 3), Janine KUTZSCHE (1), Antje WILLUWEIT (1, 3), Dagmar JÜRGENS (1, 3), Manfred WINDISCH (4), Michael WOLZT (5)
(1) Forschungszentrum Jülich, Germany, (2) Heinrich-Heine-Universität Düsseldorf, Germany, (3) Priavoid, Germany, (4) Neuroscios, Austria, (5) Medical University of Vienna, Austria
CTAD would like to thank its 2019 privileged partners for their support.

GOLD SPONSORS
CONFERENCE VENUE
Hilton San Diego Bayfront
1 Park Boulevard
San Diego, California, 92101 - USA

General information

Conference Room
All sessions will take place in the INDIGO BALLROOM

Coffee Breaks and Poster Sessions
Breaks and poster presentations will be held in the INDIGO Foyer across from the conference room.

Schedule of poster presentations
Posters P1 through P110: Displayed from Wednesday, December 4 at 2 pm to Thursday, December 5 at 6 pm.
Theme 1: Clinical trials: Methodology
Theme 2: Clinical trials: Results
Theme 3: Clinical trials: Imaging
Theme 4: Clinical trials: Biomarkers including plasma

Posters P111 through P195: Displayed from Friday, December 6 at 7:30 am to Saturday, December 7 at 1 pm any posters left after that time will be discarded.
Theme 5: Clinical trials: Cognitive and functional endpoints
Theme 6: Cognitive assessment and clinical trials
Theme 7: Behavioral disorders and clinical trials
Theme 8: Health Economics and clinical trials
Theme 9: Epidemiology and clinical trials
Theme 10: Clinical Trials: Animals Models
Theme 11: New therapies and clinical trials

Meet our poster presenters during the coffee breaks. A poster assistance desk will be available at the registration desk to locate the posters.

Lunch boxes*: To be picked up in the Indigo Terrace Foyer (only for attendees who purchased the lunch package beforehand).
*Please note that there is no possibility of buying lunches onsite.

Speaker Ready Room - Preview room - Hours of Operation
- Wednesday, December 4: 1 pm to 6 pm
- Thursday, December 5: 7 am to 7 pm
- Friday, December 6: 7 am to 7 pm
- Saturday, December 7: 7 am to 3 pm

Networking cocktail reception
Wednesday, December 4 from 7 pm to 8 pm with the CTAD band.

Networking coffee time
In addition to the regular coffee breaks we suggest that you enjoy a cup of coffee with your peers and increase your networking time around the conference starting times:
- Wednesday, December 4: 3:15 pm to 4:00 pm
- Thursday, December 5: 7:30 am to 8:00 am
- Friday, December 6: 7:30 am to 8:00 am
- Saturday, December 7: 7:30 am to 8:00 am

FREE WiFi available at CTAD
Network: CTAD2019 - Password: CTAD2019

Mobile app
An email will be sent to you closer to the event with your access codes.
CTAD 2019
Clinical Trials on Alzheimer's Disease

SAN DIEGO 2019
CTAD Congress
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on
@CTADConference  CTAD Conference  CTAD Alzheimer

#CTAD19
www.ctad-alzheimer.com
CTAD 2020
Clinical Trials on Alzheimer's Disease

Save the date

November 4-7, 2020
Boston - USA
Boston Park Plaza

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

Keck School of Medicine of USC
Alzheimer's Therapeutic Research Institute